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           Abstract 
Angela Russo 
Delineating and rationally perturbing signaling mechanisms 
 involved in metastasis 
(Under the direction of Drs. JoAnn Trejo and Pilar Blancafort) 
Metastasis is the dissemination of tumor cells from the primary locus of formation to 
other organs. During migration from the primary tumor, tumor cells need to traverse the 
vasculature, a process termed extravasation. Extravasation is a critical step in the 
metastatic cascade and nevertheless a poorly understood phenomenon. Endothelial cells 
form a barrier, which prevents cells and plasma constituents from moving into interstitial 
tissues. The disruption of the endothelial barrier leads to increased barrier permeability 
resulting in enhanced cancer cell extravasation. 
Protease-activated receptor-1 (PAR1) is a G protein-coupled receptor uniquely 
activated by proteases. PAR1 increases endothelial permeability when activated by the 
protease thrombin. Strikingly, PAR1 signaling can also mediate decreases in endothelial 
permeability when activated by activated protein C (APC), an anti-coagulant protease. In 
the first two chapters of this dissertation I examined the mechanism responsible for 
protease-selective signaling by PAR1. I specifically examined the effect of APC and 
thrombin on the activation of RhoA and Rac1 that differentially regulate endothelial 
permeability. In chapter 2 of this dissertation I also investigated whether 
compartmentalization of PAR1 in caveolae was critical for APC selective signaling and I 
demonstrated that caveolae are required for APC-selective signaling to Rac1 activation and 
endothelial barrier protection. Furthermore, in chapter 3 of this dissertation I asked whether 
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APC protection from thrombin-induced increased permeability involved desensitization of 
PAR1. And I reported that APC induces PAR1 phosphorylation and desensitizes endothelial 
cells to thrombin.  
The metastatic process also requires degradation of extracellular matrices by 
proteases present in the tumor microenvironment, especially serine proteases. Inhibition of 
these proteases has remarkable therapeutic effects against tumor progression.  
Maspin is an atypical member of the family of serine proteases inhibitors. Maspin 
inhibits the serine protease urokinase activated plasminogen and suppresses tumor growth 
and metastasis. Interestingly, maspin is silenced by epigenetic mechanisms in cancer cells. 
In chapter 4 of my dissertation I used artificial transcription factors (ATFs) as a novel 
strategy to re-activate maspin in breast cancer cells. I showed that re-expression of maspin 
by ATFs leads to reduction of tumor growth and metastasis in an in vivo xenograft animal 
model. 
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CHAPTER 1. INTRODUCTION 
1.1 Protease-activated receptor 1 implications in tumor growth and metastasis 
Metastasis involves the spread of cancer cells from a primary tumor site of formation 
to distant organs in the body. Metastasis is the leading cause of cancer patient deaths. 
Invasion is a critical step in the metastatic cascade and involves the degradation of 
extracellular matrix (ECM) proteins. ECM degradation is mediated by a network of 
pericellullar proteolytic enzymes, and is tightly controlled by protease activators and 
protease inhibitors (Jedinak A. and Maliar T. 2005). 
An important group of receptors that elicit cellular responses to extracellular 
proteases is the family of G-protein coupled protease-activated receptors (PARs). 
Protease-activated receptor 1 (PAR1) is the prototype of the PAR family and responds to 
the coagulant protease thrombin (Th). PAR1 is overexpressed in aggressive melanoma, 
colon cancer, prostate cancer and invasive breast cancer (Even-Ram S. 1998; Darmoul D. 
2004). Overexpression of PAR1 results in NIH 3T3 fibroblasts transformation (Martin C.B. 
2001) and induces hyperplasia of mammary gland epithelial cells (Nicolai S. and Blasi F. 
2003). 
In addition PARs can also be activated by tumor-generated proteases. Tumors are 
replete with proteases, including urokinase-plasminogen activator (uPA) and matrix 
metalloproteases (MMPs). Tumor cells up-regulate uPA expression, which is associated 
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with poor prognosis (Nicolai S. and Blasi F. 2003). UPA binds to its cell surface receptor 
uPAR (Bissell M.J. and Radisky D. 2001) and cleaves plasminogen to generate plasmin. 
Plasmin can proteolytically activate PAR1 (Kuliopulos A. 1999). Plasmin also degrades 
extracellular matrix proteins and cleaves and activates MMPs. The tumor microenvironment 
is also enriched with several types of MMPs, including MMP-1, which can cleave and 
activate PAR1 (Boire A. 2005). 
The mitogenic activity of PAR1, induced upon thrombin activation, is associated with 
prolonged activation of extracellular signal-regulated kinase 1,2 (ERK1,2) (Kahan C. 1992; 
Trejo J. 1996). The sustained increase in ERK1,2 signaling stimulated by thrombin not only 
promotes cell cycle progression but also contributes to cellular transformation, migration 
and survival. Our recent work demonstrated that proteolytic activation of PAR1 by thrombin 
causes sustained ERK1,2 signaling and promotes breast carcinoma cell invasion via 
persistent transactivation of ErbB family members (Arora P. 2008). The ErbB family of 
receptor tyrosine kinases includes epidermal growth factor (EGF) receptor (EGFR)/ErbB1, 
ErbB2/HER2, ErbB3 and ErbB4. ErbB family members undergo ligand-induced 
dimerization, which provokes intrinsic kinase activation, transphosphorylation of 
cytoplasmic tyrosine residues and recruitment of signaling molecules. ErbB2/HER2 is 
overexpressed in ~20–30% of human invasive breast cancers and is correlated with 
increased metastatic potential and decreased patient survival (Cobleigh M.A. 1999). 
Transactivation of EGFR by GPCRs results from the activation of the proteins containing 
a disintegrin and a metalloprotease domain (ADAMs) and/or matrix metalloprotease 
(MMPs) family members, which release membrane-anchored ligands such as heparin-
binding-EGF or transforming growth factor-  (TGF- ) (Prenzel N. 1999; Gschwind A. 2003). 
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PAR1 is also expressed in the vascular endothelial cells (Coughlin S.R. 2005) (Fig. 
1). Endothelial cells lining the intima of blood vessels form a functional barrier that controls 
exchange of proteins and cells between blood and the interstitial space. Disruption of the 
endothelial barrier contributes to pathological conditions such as vascular leakage, septic 
shock and cancer cell extravasation. Conversely, preservation of a tight intact endothelial 
barrier prevents processes that contribute to such pathological conditions. 
In response to thrombin, PAR1 promotes pro-inflammatory responses and increases 
permeability of the endothelial barrier (Bogatcheva N.V. 2002; Feistritzer C. 2005). Under 
normal conditions, pro-inflammatory responses associated with thrombin are counteracted 
by activated protein C (APC). APC inactivates up-stream coagulant proteases diminishing 
thrombin generation and elicits anti-inflammatory responses that preserve the integrity of 
the endothelial barrier (Feistritzer C. 2005). Previous studies showed that the opposing 
effects of thrombin and APC on endothelial cell permeability are both mediated by the 
activation of PAR1 (Feistritzer C. 2005). Moreover the anti-coagulant and anti-inflammatory 
properties associated with APC have been shown to be effective in treatment of septic 
shock, a severe inflammatory disorder (Baillie J.K. 2007). Recombinant APC is the only 
drug approved by FDA to treat severe sepsis. However, the molecular mechanisms by 
which APC and thrombin elicit distinct cellular responses through the same receptor remain 
poorly understood. Therefore, understanding the role of PAR1 in APC-signaling may 
provide new insight into the molecular mechanism of inflammatory disorders and cancer 
cell extravasation. The observation that different ligands acting at the same receptor can 
elicit distinct signaling responses has been reported for many GPCRs and is a process 
termed “functional selectivity” or “biased agonism” (Urban J.D. 2007). The molecular basis 
of functional selectively appears to involve ligand-induced stabilization of distinct active 
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receptor conformations. New studies now indicate that compartmentalization of GPCRs 
within membrane microdomains also facilitate stabilization of distinct active receptor 
conformations and promote receptor coupling to specific signaling effectors (Zheng H. 
2008). The proteolytic irreversible activation of PARs, which results in the unmasking of a 
tethered ligand, is distinct from most normal ligand-activated GPCRs and questioned 
whether proteases displayed biased agonism at PARs. The studies described in chapter 2 
and 3 of this dissertation reveals that compartmentalization of PAR1 in caveolae is critical 
for protease-selective activation and signaling by PAR1 (Russo A. 2009). 
1.2 The family of PARs 
PARs are a unique class of GPCRs that signal in response to extracellular 
proteases. There are four PARs encoded by distinct genes in the mammalian genome.  The 
discovery of PAR1 in 1991 resulted from a search for a receptor that conferred thrombin 
signaling and was originally dubbed the “thrombin receptor” (Vu T.K. 1991a). PAR1 is 
considered the family prototype and is the predominant mediator of thrombin signaling in 
most cell types. PAR3 and PAR4 were later discovered and also shown to elicit cellular 
responses to thrombin (Ishihara H. 1997) (Xu W.F. 1998). PAR2 was identified in a mouse 
genomic library screen using probes homologous to the transmembrane regions of the 
substance K receptor (Nystedt S. 1994). Unlike other PARs, PAR2 is activated by trypsin-
like serine proteases but not by thrombin.  
Thrombin, the main effector protease of the coagulation cascade, drives fibrin 
deposition and signals through PARs to promote platelet activation, which is critical for 
hemostasis and thrombosis (Coughlin S.R. 2005). Activation of PARs by thrombin also 
contributes to inflammatory and proliferative responses triggered by vascular injury and 
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thrombotic disease. PARs are expressed primarily in cells of the vasculature including 
platelets, immune cells, endothelial cells, fibroblasts and smooth muscle cells and exhibit 
species-specific differences in expression patterns. PAR1 and PAR4 are the functional 
thrombin receptors present on human platelets (Kahn M.L. 1999), whereas PAR3 and 
PAR4 mediate thrombin signaling in murine platelets (Kahn M.L. 1999) (Sambrano G.R. 
2001). In human endothelial cells, PAR1 is predominantly expressed together with PAR3 
(O'Brien P.J. 2000), whereas PAR4 is co-expressed with PAR1 in murine endothelial cells 
(Kataoka H. 2003). PAR2 is widely distributed and expressed in endothelial cells, 
fibroblasts, intestinal epithelial cells as well as in airway cells and mediates inflammatory 
and proliferative responses associated with tissue injury (Ramachandran R. 2008). PAR1 
and PAR2 are also expressed in sensory neurons and glial cells and initiate neurogenic 
inflammation, edema and hyperalgesia, however, the proteases that activate PARs in these 
particular cell types in vivo have yet to be identified (Traynelis S.F. and Trejo J. 2007). 
Indeed, with the exception of coagulant proteases and vascular cells, the particular 
proteases that function as the physiological regulator of PAR activation in a given tissue or 
cellular setting are not well defined.  
1.3 Activation and signaling by PARs  
The model for proteolytic activation of PARs posits that proteases cleave at a 
specific peptide bond within the N-terminus of the receptor, which results in the formation of 
a new N-terminus that acts like a tethered ligand by binding intramolecularly to the receptor 
to trigger transmembrane signaling (Fig. 2) (Vu T.K. 1991a; Vu T.K. 1991b). Consistent with 
this mode of activation, synthetic peptides that mimic the tethered ligand sequence of the 
newly exposed N-terminus can activate PARs independent of proteolytic cleavage, with the 
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exception of PAR3  (Ishihara H. 1997). Although typically proteolytic cleavage leads to 
activation of the same receptor, there is evidence of crosstalk between different PARs. In 
murine platelets and transfected cells, PAR3 binds to and localizes thrombin to facilitate 
activation of PAR4, a low affinity thrombin receptor (Nakanishi-Matsui M. 2000). PAR3 is 
efficiently cleaved by thrombin, but is less efficacious than other PARs at eliciting G protein-
dependent cellular responses in vascular cells. However, recent work indicates that 
activation of PAR3 by thrombin induces rapid Ca2+-dependent release of ATP from lung 
epithelial A549 cells, a cell line that does not express detectable PAR1 or PAR4 
(Seminario-Vidal L. 2009). In addition, PAR3 has been shown to dimerize with PAR1 and 
consequently potentiates thrombin signaling in endothelial cells, suggesting that PAR3 
functions as an allosteric modulator of PAR1 signaling in certain cell types (McLaughlin J.N. 
2007). Another type of PAR crosstalk occurs in endothelial cells, where the tethered ligand 
domain of signaling defective cleaved PAR1 transactivates PAR2 (O'Brien P.J. 2000), 
although the physiological significance of this type of intermolecular transactivation 
remained elusive. New studies indicate that during the progression of sepsis, a systemic 
inflammatory condition with disseminated intravascular coagulation activated PAR1 
switches from endothelial disruptive signaling to protective signaling via transactivation of 
PAR2, a receptor upregulated in endothelial cells during severe sepsis (Kaneider N.C. 
2007). Thus, the formation of heterodimeric complexes between PARs appears to modulate 
certain signaling responses but is unlikely to be critical for monomeric PAR coupling to 
heterotrimeric G-protein signaling (Whorton M.R. 2007). However, distinct PAR dimeric 
complexes might have other functions such as facilitating distinct protease-selective 
signaling, but this remains to be determined.  
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Once activated, PARs undergo conformational changes that facilitate coupling to 
heterotrimeric G-proteins. Activated PAR1 couples to multiple heterotrimeric G-protein 
subtypes including Gq, Gi and G12,13 and promotes diverse cellular responses (Fig. 2). 
Several early studies indicated that PAR1 couples to inhibition of cAMP accumulation 
through Gi and stimulates phospholipase C (PLC)-catalyzed hydrolysis of 
phosphoinositides (PI) and Ca2+ mobilization through Gq (Baffy G. 1994; Benka M.L. 1995), 
whereas activation of ERK1,2 occurs through both Gq and Gi signaling (Trejo J. 1996). 
Other studies have illustrated coupling of PAR1 to G12/13, which leads to activation of Rho 
GEFs, induction of cytoskeletal changes and PLC activation (Lopez I. 2001; Gohla A. 
1999).  
Previous studies questioned whether PAR3 is capable of signaling autonomously 
(Nakanishi-Matsui M. 2000). However, new work indicates that PAR3 can elicit cellular 
responses to thrombin typical of G-protein signaling in particular cell types (Seminario-Vidal 
L. 2009). Although there is no direct evidence linking PAR2 to heterotrimeric G-protein 
activation, numerous studies demonstrate that activation of PAR2 with proteases and/or 
synthetic peptide agonists increase second messenger responses suggestive of Gq, Gi and 
perhaps G12/13 signaling. Previous studies also indicate that activated PAR2 binds to and 
internalizes with β-arrestin, a multifunctional adaptor protein (DeFea K.A. 2000; Stalheim L. 
2005). Once internalized, the PAR2-β-arrestin complex functions as a scaffold to recruit 
ERK1,2 on endocytic vesicles and is thought to sustain ERK1,2 signaling in the cytoplasm 
independently of G-protein activation. The activation of distinct G-protein subtypes as well 
as non-G-protein effectors by PARs is crucial for eliciting cell type-specific responses. The 
extent to which PARs couples to distinct G-protein subtypes in a particular cell type 
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depends in part on the G-protein and effector repertoire expressed in the cells but other 
mechanisms are likely to exist.  
1.4 Multiple proteases activate PAR signaling 
In addition to thrombin, other proteases activate PAR1. Tissue factor (TF), a single 
transmembrane protein, initiates coagulation by generating thrombin through activation of 
coagulation factor VIIa and FXa and also promotes cellular signaling via activation of PARs. 
The upstream coagulation protease FXa can cleave and activate PAR1 as a monomer or in 
a complex with TF and FVIIa (Fig. 3) (Camerer E. 2000; Riewald M. 2001). Activated 
protein C (APC) bound to the endothelial protein C receptor (EPCR), a single spanning 
transmembrane protein, cleaves and inactivates FVa and VIIa diminishing thrombin 
generation and induces cellular responses through the activation of PAR1 (Riewald M. 
2002). APC, an anti-coagulant protease, is generated on the endothelial cell surface via 
activation of protein C (PC) by the thrombin-thrombomodulin complex (Fig. 3) (Stearns-
Kurosawa D.J. 1996). The plasma enriched zymogen plasminogen is cleaved by urokinase 
and tissue plasminogen activator (TPA) to generate the active enzyme plasmin, which 
degrades fibrin and also cleaves PAR1 at multiple sites, which either activates or 
incapacitates the receptor, depending on the cleavage site (Mannaioni G., (2008)) 
(Kuliopulos A. 1999). More recently, matrix metalloproteases-1 (MMP-1), also known as 
interstitial collagenase, was shown to activate PAR1 in invasive breast carcinoma but 
precisely how MMP-1 acts on PAR1 to generate a functional ligand and/or cellular signaling 
has not been clearly established (Boire A. 2005).  
Several proteases can activate PAR2 including trypsin, FVIIa in complex with TF 
and FXa, neutrophil protease-2, mast cell tryptase, membrane-tethered serine protease-1 
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and others but not thrombin (Ramachandran R. 2008). The TF-FVIIa complex can activate 
PAR2 either directly as a binary complex or indirectly through generation of FXa. FXa may 
signal more efficiently in a ternary complex with TF-VIIa than it does as a monomer. 
Interestingly, Ahamed et al. showed that a TF-VIIa complex formed with a distinct “cryptic” 
form of TF in which a specific disulfide bond is reduced fails to support coagulation, i.e. 
thrombin generation, but retains its ability to signal via PAR2 (Ahamed J. 2006). However, it 
has not been determined whether activation of PAR2 by TF-VIIa and TF-VIIa-Xa 
differentially promote distinct cellular responses and hence, questioned the physiological 
relevance of these findings (Camerer E. and Trejo J. 2006). Similar to other PARs, PAR2 
appears to be modified by N-linked glycosylation, a process that affects activation of PAR2 
by tryptase but not trypsin nor synthetic peptide agonists (Compton S.J. 2002). 
Interestingly, mutants of PAR2 in which the tethered ligand sequence SLIGRL was mutated 
to SLAAA or SAIGRL displayed robust increases in Ca2+ mobilization when activated 
proteolytically by trypsin (Al-Ani B. 2004). However, neither SLAAA nor SAIGRL synthetic 
peptides could elicit cellular responses comparable to SLIGRL, the native tethered ligand 
sequence, when added exogenously to cells. These findings suggest that cleavage of the 
receptor rather than unmasking of the entire ligand sequence is critical for proteolytic 
activation of PAR2, whereas other structural determinants are required for activation of 
PAR2 by synthetic peptide agonists. 
Similar to other PARs, PAR4 is cleaved and activated by multiple serine proteases 
including thrombin, trypsin, plasmin and cathepsin G (Coughlin S. R. 2005). Interestingly, 
both the kinetics of PAR4 activation and shut-off of signaling responses are slow resulting 
in sustained signaling, in marked contrast to other PARs (Shapiro M.J. 2000; Holinstat M. 
2006). Mechanistically how this occurs is not known. In addition, the signaling effectors and 
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cell-type specific responses triggered by activated PAR4 remain poorly characterized. 
Besides thrombin, it remains to be determined whether other proteases are capable of 
proteolytically activating PAR3, a receptor that displays autonomous signaling only in 
certain cell types. Clearly many different proteases cleave and activate PARs, however, 
whether these proteases stabilize distinct active PAR conformations to promote coupling to 
specific signaling effectors and cell-type specific responses has not been thoroughly 
investigated. However, new studies have revealed that activation of PAR1 by two different 
proteases promotes distinct cellular signaling, a phenomenon termed functional selectivity 
or biased agonism (Urban J.D. 2007). 
1.5 PAR1 displays biased agonism 
The finding that different ligands are capable of promoting distinct signaling 
responses through the activation of the same receptor has now been reported for many 
GPCRs (Urban J.D. 2007). In many cases, differences in signaling have been observed in 
studies comparing synthetic ligands to natural ligands, questioning the physiological 
significance of such findings. Indeed, early studies suggested that distinct cellular 
responses could be evoked by PAR1 when activated proteolytically by its tethered ligand 
versus untethered “free” synthetic peptide agonists (Fig. 4) (Blackhart B.D. 2000). 
McLaughlin et al. more recently demonstrated using human endothelial cells that activation 
of PAR1 with thrombin favors G12/13 signaling and induction of endothelial barrier 
permeability over Gq-dependent Ca2+ mobilization (McLaughlin J.N. 2005). In contrast, 
synthetic PAR1 peptide agonists SFLLRN and TFLLRNPNDK caused an opposite rank 
order of activation favoring Gq-triggered Ca2+ increases rather than G12/13 signaling, but 
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whether different endogenous proteases promote distinct signaling through the activation of 
PARs remained an open question.  
Several recent studies have now reported that two different proteases, thrombin and 
activated protein C, cleave and activate PAR1 but cause opposite effects on endothelial 
barrier permeability (Feistritzer C. 2005; Finigan J.H. 2005). In general, thrombin functions 
as a pro-inflammatory mediator and disrupts endothelial barrier permeability through the 
activation of PAR1 (Komarova Y.A. 2007). In contrast to thrombin, however, activation of 
PAR1 by APC elicits anti-inflammatory and promotes endothelial barrier stabilization 
(Feistritzer C. 2005; Finigan J.H. 2005). APC is generated on the endothelial cell surface 
and is poised to signal via direct activation of PAR1 (Riewald M. 2002; Feistritzer C. 2006). 
The cytoprotective and anti-inflammatory responses induced by APC also require the co-
factor function of EPCR, a single transmembrane protein (Riewald M. 2002). Moreover, 
APC has been shown clinically to reduce mortality of patients with severe sepsis (Bernard 
G.R. 2001). The molecular mechanisms by which APC distinctly activates PAR1 signaling 
are not clearly understood. 
Proteolytic activation of PAR1 requires unmasking of a tethered ligand sequence 
that binds intramolecularly to the body of the receptor stabilizing an active receptor 
conformation that triggers transmembrane signaling. Previous studies have shown that 
APC has the capacity to cleave PAR1, albeit with considerably less efficiency than thrombin 
(Ludeman M.J. 2005). Thus, the extent of PAR1 activation by APC should be different than 
thrombin, which efficiently cleaves the receptor. However, whether APC cleavage of PAR1 
is the only critical determinant that facilitates PAR1 selective signaling and endothelial 
barrier protection is not known. If cleavage of PAR1 by APC is solely responsible for 
endothelial barrier protective signaling then quantitative not qualitative differences in 
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signaling would be observed following activation of PAR1 by thrombin versus APC. To test 
this possibility, in this dissertation we examined the effect of thrombin and APC on the 
activation of RhoA and Rac1, small GTPases that differentially regulate endothelial barrier 
permeability. We initially found that thrombin and APC signaling were lost in PAR1-deficient 
endothelial cells, indicating that PAR1 is the major effector for protease signaling in these 
cells (Russo A. 2009). Surprisingly, we also found that thrombin caused robust RhoA 
signaling but not Rac1 activation, whereas APC stimulated a marked increase in Rac1 
activation but not RhoA signaling, consistent with the opposing functions of these proteases 
on endothelial barrier integrity (Russo A. 2009). Thus, the activation of PAR1 by APC likely 
results in a distinct active receptor conformation that selectively couples to effectors that 
mediate endothelial barrier protective signaling rather than disruption. 
1.6 Membrane microdomains and protease-dependent biased agonism 
How can activation of the same receptor by two different proteases elicit distinct 
cellular responses? Herein we showed that the underlying mechanisms that regulate 
coupling of proteolytically activated PAR1 to distinct signaling effectors involve localization 
to caveolae, a specific type of plasma membrane microdomain. Caveolae are lipid rafts 
enriched in cholesterol and caveolins and function as microdomains that facilitate receptor-
effector coupling and signal transduction. Indeed, we recently showed that caveolin-1 
expression is essential for APC but not thrombin activation of PAR1 signaling and 
endothelial barrier protective effects (Russo A. 2009), suggesting that PAR1 localization to 
caveolae is critical for protease-selective signaling. Previous studies also showed that the 
APC co-factor EPCR, PAR1, Gq and Gi partition into lipid rafts and associate with caveolin-
1 (Bae J.S. 2007; Li S. 1995). Caveolin-1 is a structural protein essential for caveolae 
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formation in endothelial cells (Razani B. 2001). The barrier protective signaling induced by 
APC is also blocked by pertussis toxin, suggesting a role for Gi/o in this process (Bae J.S. 
2007). Moreover, the localization of APC bound to EPCR in lipid rafts facilitates efficient 
PAR1 cleavage and activation, suggesting that perhaps caveolae localization stabilizes a 
distinct active receptor conformation that elicits barrier protective signaling (Bae J.S. 2008). 
Taken together these data suggest that PAR1, EPCR, Gi/o proteins localize to caveolae and 
exist as a preassembled complex poised to signal following APC generation on the cell 
surface. In contrast, caveolin-1 is not essential for thrombin activation of PAR1 signaling 
(Russo A. 2009), indicating that caveolin-1 only modulates PAR1 signaling when selectively 
activated by APC and not by thrombin in endothelial cells. Interestingly, a function for lipid 
rafts but not caveolae in thrombin-induced cytoskeletal changes, a cellular process 
controlled predominantly by G12/13 signaling, in endothelial cells has previously been 
reported (Carlie-Klusacek M.E. and Rizzo V. 2007). Moreover, caveolae are also required 
for TF-VIIa but not for peptide agonist activation of PAR2 but whether TF-VIIa, agonist 
peptide or trypsin promote distinct signaling responses was not examined (Awasthi V. 
2008). 
The molecular determinants that specify the targeting of PAR1 and signaling 
components to caveolae are largely unknown but may involve post-translational 
modifications. Caveolin-1 is palmitoylated and together with cholesterol and sphingolipids 
form caveolar microdomains, which sequester other lipid-modified proteins within the 
plasma membrane. A large number of GPCRs appear to be modified by palmitoylation, 
which occurs through the covalent attachment of a C16 fatty-acid chain via a thioester 
linkage to cysteine residues localized within the cytoplasmic tail of the receptor. PAR1 and 
PAR2 have cytoplasmic cysteine residues that could serve as sites for palmitoylation but to 
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our knowledge this has not been reported. Previous studies have shown that palmitoylation 
of tissue factor (TF) facilitates its localization to caveolae and prevents protein kinase C 
dependent phosphorylation, a process that controls tissue factor pro-coagulant activity 
(Dorfleutner A. and Ruf W. 2003). Thus, the modulation of TF with palmitoylation may 
facilitate localization of TF-FVIIa and Xa with PAR2 in caveolar microdomains to promote 
cellular signaling. Whether EPCR is similarly palmitoylated is not known. Interestingly, 
several studies suggest that protein palmitoylation protects proteins from ubiquitination and 
subsequent degradation (Valdez-Taubas J. 2005; Abrami L. 2006). Modification of proteins 
with ubiquitin occurs through the covalent attachment of ubiquitin, a 76-amino acid protein, 
to lysine residues on the target protein. Both PAR1 and PAR2 are ubiquitinated (Wolfe B.L. 
2007; Jacob C. 2005) but whether PAR ubiquitination facilitates receptor palmitoylation 
and/or targeting of proteins to caveolae has not been examined.  
In addition to post-translational modifications, recent work suggests that localization 
of the µ-opiate receptor (MOR) to lipid rafts is regulated by its interaction with the 
heterotrimeric Gi2 protein (Zheng H. 2008). The localization of MOR to lipid rafts was 
disrupted by cholesterol depletion as well as by altering the expression of Gi2. In the 
absence of agonist, MOR directly associated with Gi2, which is mediated by a G protein-
interaction motif, upon the deletion of this motif, the receptor redistributed out of the lipid 
microdomain. Interestingly, etorphine promoted MOR interaction with β-arrestin, which in 
turn facilitated receptor translocation out of the lipid raft, a process that required receptor 
dissociation from Gi2. By contrast, stimulation of MOR with morphine induced an activate 
receptor conformation that preferentially bound to Gi2 and showed a low affinity for arrestin, 
consistent with minimal receptor phosphorylation and lack of internalization. Thus, 
membrane microdomain association, and interaction with heterotrimeric Gi2 protein 
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regulates agonist-selective signaling by MOR. Whether PAR1 interaction with Gi2 is 
important for caveolae association and protease-selective signaling will be important to 
determine.  
The expression of β-arrestin-2 is also critical for maintaining and/or stabilizing 
distinct assemblies of the G-protein coupled serotonin 2A receptor (5-HT2AR) with 
signaling effectors  (Schmid C.L. 2008). The ablation of β-arrestin-2 expression caused 
selective loss of responses to the endogenous ligand serotonin, but not to a distinct 
synthetic ligand 2,5-dimethoxy-4-iodoamphetamine (DOI) (Schmid C.L. 2008). Interestingly, 
caveolin-1 was previously shown to interact with 5-HT2AR and to modulate its capacity to 
couple to Gq signaling (Bhatnagar A. 2004). However, whether β-arrestin affects 5-HT2AR 
localization to lipid rafts was not evaluated.  
1.7 Protease-selective mechanisms of PAR desensitization 
The ability of different ligands to promote distinct signaling responses through the 
activation of the same receptor suggests that unique active receptor conformations can be 
induced. These findings raise intriguing questions regarding the mechanisms that mediate 
desensitization of distinctly activated GPCRs. In the classic paradigm, GPCRs are initially 
desensitized by rapid phosphorylation of activated receptors by G-protein dependent 
kinases (GRKs) (Marchese A. 2008). Phosphorylation enhances receptor affinity for 
arrestin, and arrestin binding prevents receptor-G-protein interaction, thereby uncoupling 
the receptor from signaling. Arrestin also interacts with components of the endocytic 
machinery to facilitate GPCR internalization, and thereby removes activated receptor from 
signaling effectors at the plasma membrane. Within endosomes, receptor dissociates from 
their ligands, become dephosphorylated, and then returns to the cell surface in a state 
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capable of responding to ligand again. Several recent studies indicate that GPCRs 
activated by different ligands are desensitized through distinct mechanisms (Kelly E. 2008).  
Desensitization of the µ-opioid receptor (MOR) following activation by morphine 
occurs predominantly through protein kinase C-dependent phosphorylation, whereas 
DAMGO activated MOR phosphorylation is largely dependent on GRK. Interestingly, 
activation of the CC chemokine receptor 7 (CCR7) with the endogenous chemokine CCL19 
induces robust phosphorylation and arrestin-dependent desensitization (Kohout T.A. 2004). 
In contrast, a different endogenous ligand CCL21 fails to promote phosphorylation or 
arrestin-dependent desensitization of activated CCR7, suggesting that different ligands 
induce distinct desensitization of CCR7.  
The desensitization of PAR1 signaling is controlled by multiple regulatory 
mechanisms. The first involves agonist-induced PAR1 phosphorylation and the second 
involves interaction with β-arrestin. However, signaling by PAR1 appears to be more 
effectively regulated by β-arrestin-1 rather than β-arrestin-2 through a process that does not 
require receptor phosphorylation (Chen C.H. 2004; Paing M.M. 2002). In addition, activated 
PAR1 internalization and lysosomal degradation are also critical for termination of receptor 
signaling (Trejo J. 1998). Interestingly, activated PAR1 internalization occurs independently 
of arrestins (Paing M.M. 2002) (Fig. 5). Whether desensitization of PAR1 differs when 
activated proteolytically by thrombin versus synthetic peptide agonists has not been 
rigorously examined. Interestingly, however, we recently found that APC promotes PAR1 
phosphorylation and desensitization but causes negligible receptor internalization and 
degradation (Russo A. 2009).  
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1.8 The tumor suppressor serine protease inhibitor maspin 
Maspin is a multifaceted protein affecting a variety of cellular processes. Maspin is a 
tumor suppressor that exerts its function by increasing cell adhesion, inducing apoptosis 
and decreasing motility and angiogenesis (Sheng S. 1996; Seftor R.E.B. 1998; Zhang M. 
2000). The function of maspin in reducing tumor progression has been extensively studied 
in vitro, in animal models and also by assessing cancer patient survival (Shi H.Y. 2002; 
Sheng S. 1996) Maspin is expressed by normal epithelial breast cells but not in invasive 
breast cancer (Fig. 6). Maspin is silenced during metastatic progression by transcriptional 
regulation and aberrant promoter methylation (Futscher B.W. 2002; Futscher B.W., 2004). 
Maspin re-expression is a marker of improved prognosis. Indeed, evidence shows that 
restoring the expression of maspin in invasive carcinoma cells results in increased rate of 
spontaneous apoptosis, more prominent actin cytoskeleton, reduced invasive capacity, and 
altered proteasomal function. Animal studies have validated the in vitro observations. In this 
dissertation I examined whether reactivation of maspin using artificial transcription factors 
(ATFs) in vivo reduced tumor growth and metastasis. 
1.9 Subcellular localization and function of maspin 
Maspin localizes into different subcellular compartments. Maspin is predominantly 
cytoplasmic, with some membrane association, partial secretion, and nuclear localization 
(Fig. 7). The differential localization of maspin dictates its functions. The differential 
localization of maspin is determined by specific binding partners such as interferon 
regulatory factor 6 (IFN6) (Seftor R.E.B. 1998; Liu J. 2004), histone deacetylase 1 
(HDAC1), glutathione S-transferase (GST), heat shock proteins HSP70, and HSP90 (Zhang 
H. 2003). It has been proposed that the interaction of maspin with other proteins influences 
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maspin function in response to stress and to induce apoptosis. Induction of apoptosis is one 
of the most interesting effects of maspin and implicates its use as therapeutical tool in 
inhibiting tumor growth. Intracellular maspin is implicated in apoptotic responses. Ectopic 
expression of maspin leads to high levels of pro-apoptotic Bax expression (Zhang W. 2005; 
Liu J. 2004) decreased levels of Bcl-2 (Zhang W. 2005), and activation of Caspase-3 (Li Z. 
2005) and/or caspase-9 (Liu J. 2004). Some evidence indicates that maspin can function as 
an inhibitor of angiogenesis. Secreted maspin can inhibit the migration of cultured 
endothelial cells toward fibroblast growth factor (bFGF) and vascular endothelial growth 
factor (VEGF), which act as important chemoattractants during angiogenesis (Zhang M. 
2000). Maspin successfully blocks neovascularization and reduces tumor-associated 
microvessels in vivo. In addition, expression of maspin has been shown to reduce 
metastatic dissemination of tumor cells (Zhang M. S. 2000; Watanabe M. 2005). 
Extracellular maspin blocks cell detachment, motility, and invasion. Extracellular maspin 
interacts with the components of extracellular matrix such as collagens type I and III. This 
interaction contributes to the tumor-suppressive property of maspin. Furthermore, maspin 
acts as unconventional serine-protease inhibitor by binding and inhibiting the serine 
protease urokinase plasminogen activator (uPA) without affecting uPA proteolytic function. 
UPA is the principal participant of ECM degradation. Therefore maspin inhibition of uPA is 
thought to be responsible for maspin ability to block tumor invasion and metastasis 
(Mc.Gowen R. 2000; Sheng S. 1998). Silencing of maspin is associated with higher risk of 
distant metastasis in breast carcinomas (Maass N. 2001). 
19 
 
1.10 Regulation of maspin expression 
The most important regulatory mechanism for maspin involves p53. p53 is a well-
known tumor suppressor that regulates cell-cycle and has also roles in apoptosis and 
angiogenesis.  It has been demonstrated that adenoviral delivery of wild-type p53 to breast 
and prostate cancer cell lines induces maspin expression (Zhou Z. 2000). The regulation of 
maspin by p53 is believed to be one of the most important mechanisms elucidating p53 
function in inhibiting cell invasion and metastasis. This regulation occurs primarily through 
the hormone response element located within the maspin promoter. Several studies use 
delivery of cDNA using viral vectors (Watanabe M. 2005) or liposomes (Li Z. 2005) to 
overexpress maspin. It has been reported that ectopic Maspin expression reduced tumor 
growth and metastasis in vivo (Shi H.Y. 2002). However, novel strategies are developed for 
the up-regulation of the endogenous maspin in tumor cells. Tamoxifen (TAM) can also up-
regulate endogenous maspin (Khalkhali-Ellis Z. 2004). TAM is a drug commonly used for 
the treatment and prophylaxis of breast cancer which acts by competing with estrogen for 
estrogen receptor binding. 
Epigenetic mechanisms are responsible for maspin silencing in a variety of tumor cells. 
Chromatin remodeling drugs have been used to re-activate silenced endogenous maspin 
(Kulp S.K. 2006). These agents could function by loosening up the chromatin and allowing 
the access of TFs and polymerase, facilitating transcription. Examples of these types of 
drugs are methyltransferase inhibitors and histone deacetylase inhibitors. The 
methyltransferase inhibitor 5-aza-2’-deoxycytidine has been recently approved for 
therapeutic treatment (Samlowski W.E. 2005). Maspin has also been re-activated by 
treatment with HDAC inhibitors, such as Trichostatin A (TSA), Dipepside and suberoylanide 
hydroxamic acid (SAHA). The latest has been approved in clinical trials for the treatment of 
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solid and hematological tumors (Juttermann R. 1994). However, chromatin remodeling 
drugs are often not selective and result in high toxicity and acquired drug resistance in 
cancer patients (Eyupoglu I.Y. 2005). Herein I present a novel molecular strategy for the 
controlled re-activation of maspin. Specifically I designed a new inducible system that 
allows controlled ATF expression in vivo. This strategy will allow evaluating the therapeutic 
potential of ATFs in reducing tumor growth and metastasis. 
1.11 Artificial transcription factors (ATFs) design 
Artificial transcription factors (ATFs) are made of DNA-binding domains (DBDs) 
fused with transcriptional effector domains, such as activator or repressor domains (Fig. 8) 
(Blancafort P. 2004). The DBD is made of zinc fingers (ZFs) of the type of Cys2-His2. The 
ZF consist of ~30 amino acids that fold into two antiparallel β-strands and a recognition α-
helix, which makes specific contacts with the target DNA. Each ZF domain specifically 
interacts with 3 base pairs (bp) (or triplet of recognition) of DNA (Fig. 9 A) (Pavletich N.P. 
1991). ZFs bind DNA in a quasi-independent manner (there are modular) (Fig. 9 B). This 
property allows investigators to engineer “polydactyl” ZF proteins by linkage of individual ZF 
domains. A six-ZF protein will recognize 18 bp with high selectivity and affinity. An 18-bp 
site is potentially unique in the human genome and thus, 6ZF proteins have the potential to 
recognize single genes. ZF domains that recognizing specifically most of the 64 DNA 
triplets have been isolated by phage display (Segal D.J. 1999). Thus, a collection of ZF 
alpha-helical “lexicons” recognizing all these triplets is now available. Engineered ATFs can 
be generated by simply grafting the recognition alpha helix (designed to bind the 
corresponding triplet) into a given 6ZF protein that serves as “backbone”. A very useful 
database for the construction of 6ZF domains (zinc finger tools) is available to predict the 
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amino acid sequence for a zinc finger protein expected to bind to a desired target site 
(Rebar E.J. 1994). The ZFs are fused with activator or repressor domains and thus, can 
regulate specifically endogenous genes (Fig. 10 A and B) (Blancafort P. 2004) (Beerli R.R. 
1998). 6ZF proteins targeting 18-bps are able to regulate their target genes with unique 
specificity (Segal D.J. 2003). The Blancafort lab has constructed ATFs able to up-regulate 
the tumor suppressor maspin that is silenced in metastatic breast cancer cells (Beltran A. 
2007). In addition, these ATFs were able to synergize with current methyltransferase and 
HDAC inhibitors, increasing the targeting efficiency and specificity of these small molecules. 
Herein, I describe the development of an inducible vector system to express the ATF in an 
animal model of breast cancer. 
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Fig. 1. Protease-activated receptor-1 functions in the vasculature and in cancer 
progression. Thrombin, the main effector protease of the coagulation cascade, activates 
PAR1, to elicit signaling in a variety of cell types. Thrombin activates PAR1 in human 
platelets and generates fibrin, which is important for thrombus formation and tumor cell 
survival and metastasis. PAR1 is also cleaved and activated by tumor-generated proteases, 
which contribute to tumor cell growth, invasion and metastasis. PAR1 is expressed in 
endothelial cells and responds to thrombin leading to increased endothelial permeability. 
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Fig. 2. Protease-activated receptor-1 signals to different G proteins. Thrombin binds to 
and cleaves the extracellular amino-terminal domain of PAR1, exposing a new N-terminal 
that acts like a tethered ligand to elicit transmembrane signaling. Upon thrombin activation, 
PAR1 couples to multiple heterotrimeric G-protein subtypes including Gq, Gi and G12,13 and 
promotes diverse cellular responses. PAR1 couples to inhibition of cAMP accumulation 
through Gi and stimulates phospholipase C (PLC)-catalyzed hydrolysis of 
phosphoinositides (PI) and Ca2+ mobilization through Gq. PAR1 also couple to G12/13, which 
leads to activation of Rho GEFs, induction of cytoskeletal changes and PLC activation. 
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Fig. 3. Activated protein C (APC) signals through PAR1 to promote endothelial 
cell barrier protection. Tissue factor (TF), a single transmembrane protein, initiates 
coagulation by generating thrombin through activation of coagulation factor VIIa and FXa 
through the extrinsic pathway. Thrombin elicits responses through activation of PAR1. 
Thrombin is rapidly sequestered by thrombomodulin (TM) which facilitate cleavage of 
protein C (PC) to generate activated protein C (APC). APC bound to endothelial protein C 
receptor (EPCR), a single spanning transmembrane protein, cleaves and inactivates FVa 
and VIIa diminishing thrombin generation. APC also exerts endothelial barrier protection 
through activation of PAR1. 
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Fig. 4. Proteases and peptide agonist display biased agonism at protease-
activated receptor 1. Thrombin-activated PAR1 favors G12/13 signaling and induction of 
endothelial barrier permeability over Gq-dependent Ca2+ mobilization. In contrast, synthetic 
PAR1 peptide agonists SFLLRN and TFLLRNPNDK caused an opposite rank order of 
activation favoring Gq-triggered Ca2+ increases rather than G12/13 signaling. 
Activated protein C (APC), cleaves and activates PAR1 and acts through Gi. causing 
opposite effects on endothelial barrier permeability. APC  
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Fig. 5. Mechanisms of PAR1 desensitization and down-regulation The desensitization 
of PAR1 signaling is controlled by multiple regulatory mechanisms. The first involves 
agonist-induced PAR1 phosphorylation and the second involves interaction with β-arrestin. 
In addition, activated PAR1 internalization and lysosomal degradation are also critical for 
termination of receptor signaling. Interestingly, activated PAR1 internalization occurs 
independently of arrestins whereas arrestins are required for receptor desensitization. 
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Fig. 6. Maspin is silenced by epigenetic mechanisms in invasive breast cancer cells.  
Maspin promoter is acethylated and not methylated in normal breast cells resulting in 
relaxed chromatin that allows maspin expression. Conversely, Maspin promoter is de-
acethylated and methylated in invasive breast cancer cells (MDA-MB-231) resulting in 
condensed chromatin that does not allow maspin expression.  
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Fig. 7. Maspin functions are dictated by protein localization. Extracellular and secreted 
maspin reduces cell invasion and motility by inhibiting extracellular matrix degradation.  
Intracellular maspin is responsible for cancer cell selective apoptosis.  
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Fig. 8. Artificial Transcription Factors (ATFs) function. ATFs are made of DNA biding 
domain (DBD) responsible for target specificity and effector domain (ED). The effector 
domain can be an activator or a repressor which will dictate whether the target gene will be 
up-regulated or down-regulated.  
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Fig. 9. The Cys2-His2 Zinc Finger domain structure and its interaction with DNA. (A) A 
zinc finger is a protein containing a Zinc++ cation chelated to two cysteine amino acids each 
on an antiparallel β sheet, and two histidine amino acids on a single α helix. (B) Each ZF 
interacts with 3bp on the DNA.  
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Fig. 10. Designing Artificial Transcription Factors (ATFs) to up-regulate tumor 
suppressor gens. (A) ATFs are made of six zinc finger domains fused to the activator 
domain VP64. (B) Each 6ZF recognizes a 18bp sequence in the promoter.  ATF-126 has 
been shown to be the most effective in regulating maspin promoter in breast cancer cell 
lines. Adapted from (Beltran A. 2006.)  
  
 
CHAPTER 2. APC PROTECTIVE EFFECT ON ENDOTHELIAL BARRIER REQUIRES 
CAVEOLIN-1
2.1: Abstract 
PAR1 is a G protein-coupled receptor uniquely activated by proteolysis. Thrombin, a 
coagulant protease, induces inflammatory responses and endothelial barrier permeability 
through the activation of PAR1. Activated protein C (APC), an anti-coagulant protease, also 
activates PAR1. However, unlike thrombin, APC elicits anti-inflammatory responses and 
protects against endothelial barrier dysfunction induced by thrombin. We found that 
thrombin and APC signaling were lost in PAR1-deficient endothelial cells, indicating that 
PAR1 is the major effector of protease signaling. To delineate the mechanism responsible 
for protease-selective signaling by PAR1, we examined the effect of APC and thrombin on 
the activation of RhoA and Rac1, small GTPases that differentially regulate endothelial 
barrier permeability. Thrombin caused robust RhoA signaling but not Rac1 activation, 
whereas APC stimulated a marked increase in Rac1 activation but not RhoA signaling, 
consistent with the opposing functions of these proteases on endothelial barrier integrity. 
Strikingly, APC signaling and endothelial barrier protection effects were abolished in cells 
lacking caveolin-1, whereas thrombin signaling remained intact. These findings suggest that 
compartmentalization of PAR1 in caveolae is critical for APC selective signaling to Rac1 
activation and endothelial barrier protection.  
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2.2: Introduction 
The coagulant protease thrombin is generated in response to vascular injury and in 
thrombotic disease and drives fibrin deposition and platelet activation, which are critical for 
hemostasis and thrombosis (Coughlin S.R. 2005). Thrombin promotes pro-inflammatory 
responses and disrupts endothelial barrier permeability (Komarova Y.A. 2007). PAR1 is the 
predominant mediator of thrombin responses in cells. Thrombin activates PAR1 by cleaving 
the N-terminal domain generating a new N-terminus that binds intramolecularly to the 
receptor to trigger transmembrane signaling (Vu T.K. 1991a). Synthetic peptides that 
represent the newly formed N-terminus of PAR1 can activate the receptor independent of 
thrombin and proteolytic cleavage. Interestingly, thrombin and peptide agonists differ in 
their capacity to promote endothelial barrier permeability and Ca2+ mobilization (McLaughlin 
J.N. 2005). These studies suggest that distinct cellular responses can be evoked by the 
same receptor when activated proteolytically by the tethered ligand versus untethered “free” 
synthetic peptide agonists. Similar phenomena have been reported for other GPCRs 
activated by different ligands and this is a poorly understood process termed functional 
selectivity (Urban J.D. 2007). 
APC, an anti-coagulant protease, displays cytoprotective and anti-inflammatory 
activities and has been shown clinically to reduce mortality of patients with severe sepsis 
(Bernard G.R. 2001). APC is generated on the endothelial cell surface via activation of 
protein C (PC) by the thrombin-thrombomodulin complex (Stearns-Kurosawa D.J. 1996). 
APC bound to endothelial protein C receptor (EPCR) cleaves and inactivates factors Va 
and VIIa diminishing thrombin generation and induces cellular responses through the 
activation of PAR1 (Mosnier L.O. 2003; Riewald M. 2002). In contrast to thrombin, however, 
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APC elicits anti-inflammatory responses and promotes endothelial barrier stabilization 
(Feistritzer C. 2005; Finigan J.H. 2005). The mechanism by which APC exerts anti-
inflammatory and cytoprotective signaling in endothelial cells is not fully understood. 
Previous studies suggest that most endogenous PC is bound to EPCR on the 
endothelial cell surface and cleaved by the thrombin-thrombomodulin complex (Feistritzer 
C. 2006). The newly formed APC is then poised to signal via direct activation of PAR1. 
Thus, APC generation on the endothelial cell surface is linked mechanistically to PAR1 
protective signaling. The cytoprotective and anti-inflammatory responses induced by APC 
also require the co-factor function of EPCR (Riewald M. 2002; Taylor F.B. 2000). 
Interestingly, thrombomodulin, EPCR and PAR1 partition into lipid rafts and co-fractionate 
with caveolin-1, a structural protein essential for caveolae formation in endothelial cells 
(Razani B. 2001), suggesting that these proteins reside at least partially in caveolar 
microdomains, a subtype of lipid rafts (Bae J.S. 2007a; Bae J.S. 2007b). However, whether 
caveolae are required for APC activation of PAR1 signaling and endothelial barrier 
protective effects is not known.  
Our studies here reveal a critical role for caveolae in APC, but not thrombin, 
activation of PAR1 signaling and endothelial barrier protection. These findings are the first 
to demonstrate an essential role for caveolae in agonist selective signaling by PAR1.  
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2.3: Results 
2.3.1: APC signals through PAR1 to activate the signal-regulated kinases ERK1,2 and 
the small GTPase Rac1.  
To determine whether PAR1 is essential for protease-selective signaling, we examined 
thrombin and APC signaling in human endothelial cells stably expressing a PAR1-specific 
shRNA (Arora P. 2008). In control cells, thrombin and APC induced a similar biphasic 
increase in extracellular signal-regulated kinase 1, 2 (ERK1,2) activity (Fig. 11 A). ERK1,2 
activation by APC required APC catalytic activity (Fig. 12). 
Endothelial cells expressing PAR1 shRNA displayed minimal PAR1 expression and 
signaling, whereas PAR2 signaling remained intact (Fig. 13 A and B), indicating loss of 
functional PAR1.  
However, cells lacking PAR1 displayed minimal ERK1,2 activation in response to various 
concentrations of thrombin or APC compared to control cells (Fig. 14 A and B). Thrombin 
stimulated p38 MAP kinase activation (Fig. 11 B) which was also lost in cells deficient in 
PAR1 expression (Fig. 13 C). In contrast to thrombin, APC failed to stimulate p38 MAP 
kinase signaling (Fig. 11 B). These findings suggest that PAR1, and not another receptor or 
factor, is critical for thrombin and APC signaling in endothelial cells.  
We next examined endothelial barrier permeability. Thrombin-stimulated endothelial barrier 
permeability was blocked in cells preincubated with APC (Fig. 15 A). These findings are 
consistent with a role for APC in stabilization of endothelial cell-cell junctions and protection 
against endothelial barrier dysfunction induced by thrombin (Feistritzer C. 2005). We also 
evaluated the effect of thrombin and APC on the activation of endogenous RhoA and Rac1. 
Activation of RhoA promotes endothelial barrier dysfunction, whereas Rac1 signaling has 
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been implicated in endothelial barrier stabilization (Komarova Y.A. 2007). Thrombin induced 
RhoA activation but not Rac1 signaling (Fig. 15 B and C). In contrast, APC stimulated Rac1 
activation and minimal RhoA signaling (Fig. 15 B and C). Thus, thrombin and APC have the 
capacity to elicit distinct signaling pathways and differentially regulate endothelial barrier 
permeability. Moreover, APC-stimulated increase in Rac1 activation was lost in endothelial 
cells deficient in PAR1 expression (Fig. 15 D).  
These studies demonstrate that endogenous PAR1 is essential for APC signaling 
and raises the question of how activation of the same receptor by two different proteases 
elicits distinct signaling responses in endothelial cells.  
2.3.2: Caveolae are required for APC signaling through PAR1 and APC-mediated 
signaling and endothelial barrier protection. 
PAR1 and EPCR localize to lipid rafts and associate with caveolin-1 (Bae J.S. 
2007a), but whether caveolae are essential for APC signaling and endothelial barrier 
protection has not been determined. To examine the role of caveolae in thrombin and APC 
signaling we generated endothelial cells stably expressing a caveolin-1 (CAV1) shRNA to 
ablate caveolin-1 expression (Fig. 16 A) (Schuck S. 2004). Importantly, the amount of cell 
surface PAR1 and EPCR was similar in control and caveolin-1 lacking cells (Fig. 16 B and 
C), suggesting that caveolae deficiency does not globally disrupt protein expression at the 
cell surface. Interestingly, thrombin activation of ERK1,2 was comparable in control and 
caveolin-1 deficient endothelial cells (Fig. 17 A), indicating that caveolae are not essential 
for thrombin signaling. Remarkably, however, activation of ERK1,2 by APC was lost in 
caveolin-1 deficient endothelial cells examined at early and late times (Fig. 17 B and C). 
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These findings suggest that caveolae are critical for activation of PAR1 signaling by APC 
but not thrombin. 
We next investigated the function of caveolae in APC-induced Rac1 activation and 
endothelial barrier protection. APC stimulated a marked increase in Rac1 activation in 
control cells that was virtually abolished in endothelial cells lacking caveolin-1 (Fig. 18 A). 
These findings provide further evidence that caveolae are essential for APC activation of 
PAR1 signaling. Moreover, APC pretreatment failed to protect caveolin-1 deficient 
endothelial cells from thrombin-induced endothelial barrier permeability (Fig. 18 B), 
consistent with loss of APC signaling in caveolin-1 defective cells. Thus, the 
compartmentalization of PAR1 in caveolae is essential for APC activation of PAR1 
protective signaling in endothelial cells.  
2.4: Discussion 
In the present study, we define a novel function for caveolae in protease-selective 
signaling by PAR1. We show that endogenous PAR1 is required for thrombin and APC 
signaling in endothelial cells. We further demonstrate that caveolin-1 is essential for 
activation of PAR1 signaling by APC but not thrombin, indicating that caveolae are critical 
for protease-selective signaling by PAR1. Caveolae are also required for activation of PAR2 
by tissue factor-factor VIIa but not the synthetic peptide agonist in transformed cells 
(Awasthi V. 2008), consistent with a role for caveolae in protease-selective signaling. 
Moreover, a function for lipid rafts but not caveolae, in thrombin-induced cytoskeletal 
changes in endothelial cells has previously been reported (Carlie-Klusacek M.E. and Rizzo 
V. 2007). 
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Thrombin activated PAR1 couples to Gαq, Gα12/13, and RhoA signaling, which 
induces endothelial barrier dysfunction (Komarova Y.A. 2007). In contrast, we show that 
APC activated PAR1 stimulates Rac1 but not RhoA, signaling and promotes endothelial 
barrier protection. Thus, the activation of PAR1 by APC may result in a distinct active 
receptor conformation that selectively couples to different signaling pathways. We further 
show that caveolin-1 is essential for APC but not thrombin activation of PAR1 signaling and 
endothelial barrier protective effects, suggesting that PAR1 localization to caveolae is 
critical for protease-selective signaling. Previous studies have shown that the APC co-factor 
EPCR, PAR1, Gαq and Gαi partition into lipid rafts and interact with caveolin-1 (Bae J.S. 
2007a) (Bae J.S. 2007b) (Li S. 1995). The barrier protective signaling induced by APC is 
also blocked by pertussis toxin, suggesting a role for Gαi/o proteins in this process (Bae J.S. 
2007a). Moreover, the binding of APC to EPCR facilitates efficient PAR1 cleavage in lipid 
rafts and endothelial barrier signaling, suggesting that caveolae localization may induce a 
distinct active receptor conformation that elicits barrier protective signaling (Bae J.S. 2008). 
Thus, PAR1, EPCR and Gαi/o proteins localize to caveolae and may exist as a 
preassembled complex poised to signal following PC binding to EPCR and generation of 
APC. In contrast, caveolin-1 is not essential for thrombin activation of PAR1 signaling, 
indicating that caveolin-1 only modulates PAR1 signaling when selectively activated by 
APC and not by thrombin in endothelial cells.  
Our studies provide new insight into the molecular mechanisms responsible for 
protease-selective signaling by PAR1. Evidence presented here suggests that 
compartmentalization of PAR1 in caveolae facilitates selective endothelial barrier protective 
signaling (Fig. 19). The molecular determinants that specify the targeting of PAR1 to 
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caveolae are not known but may involve unique posttranslational modifications. The novel 
regulation of PAR1 signaling by APC is also critical for endothelial barrier protection.  
2.5: Materials and methods 
Reagents and Antibodies 
Human α-thrombin was purchased from Enzyme Research Laboratories. Human APC and 
active site blocked APC-DEGR (dansyl-EGR chloromethyl ketone) were from Hematologic 
Technologies (Essex Junction, VT). The peptides agonists, TFLLRNPNDK and SLIGKV 
were synthesized at the UNC Peptide Facility, Chapel Hill, NC. Hirudin and actin antibody 
were obtained from Sigma (St. Louis, MO). Caveolin-1 antibody was from BD Biosciences 
(San Jose, CA). Horseradish peroxidase (HRP)-conjugated goat anti-mouse and -rabbit 
secondary antibodies were from Bio-Rad (Richmond, CA). 
[myo-3H]Inositol was purchased from American Radiolabelled Chemicals Inc.  Monoclonal 
anti–phospho-p44/42 mitogen-activated protein kinase [MAPK; extracellular signal- 
regulated kinase (ERK 1,2) antibody and polyclonal anti–p44/42 MAPK (ERK1,2) antibody 
were from Cell Signaling Technology, Inc. (Beverly, MA). Anti-phospho-p38 and anti-p38 
were from Cell Signaling Technology, Inc. (Beverly, MA). Anti-actin antibody was purchased 
from Sigma-Aldrich. Anti-caveolin1 and Anti-Rac1 antibodies were from Transduction 
Laboratory. Anti-RhoA was from Santa Cruz Biotech. Horseradish peroxidase-conjugated 
goat anti-mouse and anti-rabbit secondary antibodies were from Bio-Rad (Richmond, CA).  
 
Cell lines 
EA.hy926 cells were obtained from Coragene Edgell (UNC-Chapel Hill). Cells were 
manteined in DMEM plus 10 % FBS and passaged once a week. 
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EA.hy926 cells expressing PAR1 shRNA or CAV1 shRNA 
The short hairpin RNAi (shRNA) 5’- AGAUUAGUCUCCAUCAAUA-3’ targeting PAR1 and 
non-specific siRNA 5’-CUACGUCCAGGAGCGCACC-3’ were subcloned into pSilencer 5.1-
U6 Retro (Ambion, Austin, TX) as described (Coughlin S.R. 2005). The caveolin-1 shRNA 
(5’-AAGATGTGATTGCAGAACCAGA-3’) construct in pRVH1-puro was obtained from K. 
Simons and scrambled shRNA 5' –GTAAATGCCATACCTTATA-3' of PAR1 siRNA 
sequence was inserted into pSUPER.retro.puro vector (Oligoengine, Seattle, WA). 
Retroviruses were generated using PA317 packaging cells and used to infect EA.hy926 
cells. Mass populations of cells stably transduced with PAR1 shRNA, caveolin-1 shRNA, 
non-specific, scrambled shRNAs and vector control constructs were selected with 0.6 µg/ml 
of puromycin.  
 
RhoA and Rac1 Activity Assays  
GST-rhotekin RBD and PAK-PBD were purified and assays were conducted as described 
below. EA.hy926 endothelial cells were plated in 6-well dishes at 5 X 105 cells per well, 
grown for two days, deprived of serum and then treated with or without agonists for various 
times at 37°C. To assess RhoA activation, cells were lysed in buffer containing 50 mM Tris-
HCL, pH 7.6, 500 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 20 mM 
MgCl2 with protease inhibitors. Endogenous RhoA activity was then measured in pull-down 
assays using a GST fusion of the Rho binding domain (RBD) of Rhotekin. To monitor Rac1 
activity, cells were lysed in buffer containing 50 mM Tris-HCL, pH 7.6, 150 mM NaCl, 1% 
Triton X-100, 20 mM MgCl2 with protease inhibitors and then incubated with GST-p21-
activated kinase (PAK-1) binding domain (PBD) fusion protein. The GST PAK-PBD and 
Rhotekin-RBD fusion constructs were transformed into BL21 (DE3) E. coli and fusion 
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proteins were induced and prepared using standard techniques. GST- PAK-PBD (120 mg) 
or Rhotekin-RBD (90 mg) bound to glutathione-Sepharose beads were then incubated with 
cell lysates for 1 h at 4°C and washed. GTP-bound RhoA or Rac1 were eluted in 2X SDS-
sample buffer containing 100 mM Tris-HCl, pH 6.8, 20% glycerol, 4% SDS, 0.02% 
bromophenol blue, resolved by SDS-PAGE and transferred to membranes. The amount of 
endogenous activated RhoA and Rac1 were then detected by immunoblotting using a 
monoclonal anti-RhoA antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or a 
monoclonal anti-Rac1 antibody from BD Biosciences, respectively. Immunoblots were 
developed with enhanced chemiluminescence (ECL) (Amersham Biosciences, Inc., 
Arlington, IL), imaged by autoradiography, and quantitated using a Bio-Rad Fluor-S- 
MultiImager (Richmond, CA). 
 
ERK1,2 and p38 activation 
EA.hy926 cells were plated in 24-well dishes at a density of 0.7x 105 per well. Cells were 
serum-starved in 0.2% FBS over-night. The cells were pre-incubated in the absence of 
serum for 2 hrs and then treated with 10nM thrombin or 5 nM APC plus 0.5U/ml of Hirudin 
or left untreated. Then the cells were lysed in 2x SDS-gel loading buffer [100 mmol/L Tris-
HCl (pH 6.8), 20% glycerol, 4% SDS, 0.02% bromophenol blue]. Cell lysates were resolved 
by SDS-PAGE, transferred to membranes, and immunoblotted with an anti–phospho-
p44/42 MAPK (ERK1,2) or anti-phospho p38 antibodies (Cell Signaling). To detect total 
p44/42 MAPK (ERK1,2), membranes were stripped and reprobed with an anti–p44/42 
MAPK (ERK1,2) or anti p38 antibodies. Immunoblots were developed, imaged, and 
quantitated using a Bio-Rad Fluor-S MultiImager.  
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Cell surface ELISA 
To follow cell surface PAR1 expression, EA.hy926 endothelial cells were plated at 70% 
confluence on 24-well culture dishes (Falcon), grown for two days and then incubated with 
or without agonist for various times at 37 °C. fixed w ith 4% paraformaldehyde for 5 min at 4 
°C, washed, and incubated with anti-PAR1 antibody C54 33, washed incubated with 
secondary horseradish peroxidase-goat anti-rabbit GAR-HRP. The amount of bound 
secondary antibody was determined by incubation with 1-Step ABTS (2,2'-azinobis-3-
ethylbenz-thiazoline-6-sulfonic acid) (Pierce) substrate for 10–20 min at 25 °C. An aliquot 
was removed, and the optical density determined at 405 nm using a Molecular Devices 
SpectraMax Plus microplate reader.  
 
 Immunoblotting 
 EA.hy926 endothelial cells were plated at 70% density on 24-well culture dishes (Falcon). 
The cells were starved overnight in 0.2% FBS. The cells were pre-incubated in the absence 
of serum for 2 hrs and then treated with 10nM thrombin or 5 nM APC plus 0.5U/ml of 
Hirudin or left untreated. The cells were lysed in Laemmli lysis buffer. Lysates were 
resolved by SDS-PAGE, transferred, and immunoblotted with anti-caveolin1 antibody (BD). 
Immunoblots were developed with ECL-PLUS (Amersham Biosciences, Inc.), developed by 
the enhanced chemiluminescence ECL system (Amersham Biosciences) and visualized by 
exposure to film.  Membranes were then stripped and reprobed with anti-actin antibody. 
 
 Phosphoinositide Hydrolysis 
 Cells plated in 12-well dishes and labeled with 2 µCi/ml of [myo-3H]inositol in serum-free 
DMEM containing 1 mg/ml BSA overnight. Cells were washed and then incubated in the 
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absence or presence of agonist diluted in DMEM, 1 mg/ml BSA containing 20 mM lithium 
chloride for various times at 37 °C. Cell incubation me dium was removed, and total cellular 
[3H]inositol phosphates ([3H]IPs) were extracted, isolated, and quantitated as described 
previously (Paing M.M. 2002).  
 
Permeability Assay  
Endothelial barrier permeability was quantified by measuring the flux of Evans blue-bound 
bovine serum albumin (BSA) (Sigma, St. Louis, MO). Briefly, EA.hy926 cells (5 X 104 cells 
per well) were plated on 12-mm diameter transwell dishes coated with 2% gelatin (3-µm 
pore size polycarbonate filter; Costar, Corning, NY) and grown for 4-6 days at 37°C. The 
upper and lower chambers contained 500-µL and 1500-µL growth media, respectively. The 
day before the experiment, the growth medium was replaced with starvation medium 
(DMEM containing 0.2% FBS). On the day of the experiment, cells were washed and then 
incubated with or without 10 nM APC for 3 h at 37°C,  added to the upper chamber. Cells 
were washed, and then incubated with or without 10 nM thrombin or 10 nM APC for 10 to 
20 min at 37°C added to the upper chamber. The mediu m in the upper chamber was then 
replaced with 0.67 mg/mL Evans blue-BSA diluted in growth medium containing 4% BSA 
(Sigma) and after 10-20 minutes the optical density (OD) at 650 nm was measured in a 1: 3 
diluted 50 µL sample from the lower chamber using a Molecular Devices Plate Reader 
(Sunnyvale, CA).  
 
Data Analysis 
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Data were analyzed using Prism 4.0 software (GraphPad), and statistical significance was 
determined using InStat 3.0 (GraphPad). Group comparisons were made using an unpaired 
t-test.  
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Fig. 11. Activation of ERK1,2 and p38 signaling by thrombin and APC. (A) and (B) 
Serum-starved endothelial cells were incubated in the absence or presence of 10 nM 
thrombin (Th) or 10 nM APC (with 0.5 U/ml hirudin) for various times at 37°C. ERK1,2 and 
p38 activation were then determined using specific anti-phospho mitogen-activated protein 
kinase (MAPK) antibodies. Membranes were stripped and reprobed for total MAPK.  
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Fig. 12. Catalytic activity of APC is required for ERK1,2 activation. Serum-starved wild-
type EA.hy926 endothelial cells were incubated in the absence or presence of 10 nM APC 
or active site blocked 10 nM APC-dansyl-EGR chloromethyl ketone (DEGR) for 5 min or 90 
min at 37°C. Cells were lysed and ERK1,2 activity was determined by immunoblotting. 
Membranes were stripped and re-probed with anti-actin antibody as a control for loading. 
These findings were observed in several separate experiments.  
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Fig. 13. Thrombin signaling is lost in EA.hy926 endothelial cells expressing PAR1 
shRNA. (A) Equivalent amounts of lysates prepared from control and PAR1 shRNA 
expressing cells were immunoprecipitated with monoclonal anti-PAR1 antibody or IgG 
control. Immunoprecipitates were immunoblotted with anti-PAR1 polyclonal antibody to 
detect PAR1 expression. (B) Control and PAR1-deficient endothelial cells labeled with myo-
[3H]inositol were incubated in the presence or absence of 10 nM thrombin (Th) or 100 µM 
SLIGKV (PAR2agonist peptide) for 60 min at 37°C in medium containing lithium chloride. 
The amounts of accumulated [3H]IPs were then measured. The data are shown as total 
[3H]inositol phosphates (cpm) accumulated and expressed as fold-increase over untreated 
control. (C) Serum-starved control and PAR1 deficient cells were incubated with or without 
various concentrations of thrombin (Th) for 5 min at 37°C. Cells were lysed and activation 
of p38 was determined using anti-phospho p38 antibody. Membranes were reprobed with 
total p38 antibody to control for loading.  
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Fig. 14. PAR1 is essential for thrombin and APC signaling in to ERK1,2 endothelial 
cells. (A) and (B) Serum-deprived control and PAR1 shRNA-expressing EA.hy926 
endothelial cells were incubated with thrombin or APC (0.5 U/ml hirudin) for 5 min at 37°C 
and ERK1,2 activity was determined by immunoblotting. Theses data are representative of 
three independent experiments.  
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Fig. 15. Thrombin and APC differentially activate endothelial permeability and RhoA 
and activation. (A) Confluent EA.hy926 cells were preincubated with or without 10 nM 
APC for 3 h at 37°C in medium containing 0.5 U/ml hi rudin and then treated with 10 nM 
APC or 10 nM thrombin (Th) for 20 min at 37°C and e ndothelial barrier permeability was 
performed. The data (mean ± S.D., n=3) are representative of three independent 
experiments. (B) and (C) Cells were incubated with or without 10 nM thrombin (Th) or 10 
nM APC (0.5 U/ml hirudin) at 37°C. Cells were lysed a nd activated RhoA and Rac1 were 
detected by immunoblotting. The data are representative of three separate experiments. (D) 
Control and PAR1 deficient endothelial cells were incubated with or without 10 nM APC for 
5 min at 37°C and activation of Rac1 was determined. The data (mean ± S.E.) are 
expressed as the fold-increase over untreated control and are the averages of three 
independent experiments.  The difference between Rac1 activation induced by APC in 
control versus PAR1-deficient cells was significant (*, P<0.05). 
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Fig. 16. Caveolin-1 knock-down does not affect PAR1 and EPCR cell surface 
expression. (A) Cells were lysed and protein extract was processed by SDS-PAGE and 
dectected using antibodies. (B) and (C) Control and caveolin-1 (CAV1) deficient endothelial 
cells were fixed, and the amounts of cell surface PAR1 and EPCR at steady state were 
determined by ELISA. The data (mean ± S.D., n=3) are representative of replicate 
experiments.  
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Fig. 17. Caveolin-1 is required for APC but not thrombin-induced ERK1,2 activation. 
Serum-deprived caveolin-1 shRNA expressing EA.hy926 endothelial cells were incubated 
with 10 nM thrombin (A) or 10 nM APC (0.5 U/ml hirudin) (B) for 5 min or 90 min (C) at 
37°C. Cells were lysed and ERK1,2 activity was determined by immunoblotting. The 
membranes were stripped and reprobed with an anti-actin antibody to control for loading. 
Similar results were observed in multiple independent experiments.  
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Fig. 18. Caveolin-1 is essential for APC-induced Rac1 activation and endothelial 
barrier protection. (A) Control and caveolin-1 (CAV-1) deficient cells were incubated with 
or without 10 nM APC at 37°C and Rac1 activation was d etermined. The data (mean ± 
S.E.) are expressed as fold-increase over control and are the averages of three different 
experiments. The difference between Rac1 activation induced by APC in control versus 
CAV-1 deficient cells was significant (*, P<0.05). (B) Control and CAV-1 deficient cells were 
treated with or without 10 nM APC for 3 h at 37°C a nd then incubated with 10 nM thrombin 
(Th) or 10 nM APC for 10 min at 37°C and permeabili ty was monitored. The data (mean ± 
S.E.) are the averages of three independent experiments performed in triplicate. The 
difference between thrombin-induced permeability in control versus CAV-1 deficient cells 
was significant (*, P < 0.05). 
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Fig. 19. Schematic of caveole-dependent selective signaling of PAR1. Thrombin-
activated PAR1 mediates increases in permeability through RhoA activation. Conversely, 
APC-activated PAR1 leads to activation of Rac1 and protects endothelial barrier. 
 
 
 
  
 
CHAPTER 3: APC PREVENTS THROMBIN-INDUCED ENDOTHELIAL BARRIER 
DISRUPTION BY DESENSITIZING PAR1 SIGNALLING RESPONSE TO THROMBIN 
3.1: Abstract 
Activated protein C (APC) is known to maintain endothelial barrier integrity and also to 
protect against thrombin induced disruption of endothelial barrier (Feistritzer C. 2005). 
However, the mechanism underlying APC inhibition of thrombin induced endothelial 
disruption is not known. Here, I investigated whether APC exerts its endothelial barrier 
protective function by desensitizing PAR1 to further stimulation by thrombin. I show that 
APC pretreatment inhibits thrombin-induced signaling to ERK1,2, p38 and RhoA activation. 
Phosphorylation of activated PAR1 is the initial event critical for uncoupling the receptor 
from G-protein signaling (Ishii K. 1995). In addition to phosphorylation, internalization and 
lysosomal degradation are also critical for the regulation of PAR1 signaling (Coughlin S.R. 
1999). I show that APC promotes phosphorylation of endogenous PAR1 in human 
endothelial cells. However, in contrast to thrombin I demonstrated that APC does not affect 
PAR1 internalization or degradation suggesting a new molecular mechanism for APC 
regulation of PAR1 signaling. 
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3.2: Introduction 
Persistent activation of receptors results in the eventual loss of receptor-activated function 
or desensitization. Three general temporarely distinct mechanisms are associated with 
desensitization of G-protein coupled receptors. The first involve GPCR phosphorylation by 
GRKs or second messenger kinases that uncouple the receptor from G-proteins. Once 
phosphorylated, activated GPCRs are rapidly internalized, removing activated receptors 
from signaling effectors. Receptor internalization may involve different membrane trafficking 
pathways involving either caveolae, clathrin-coated, or non-coated vesicles. Internalized 
receptors can then either recycle back to the cell-surface or enter the endocytic pathway 
and eventually be degraded in lysosomes. Both receptor phosphorylation and 
internalization are associated with rapid receptor desensitization, which occurs within 
minutes. With prolonged agonist exposure, a slower phase (typically hours) of receptor 
down-regulation occurs in which the steady-state level of receptor protein is diminished.  
Mechanisms responsible for the agonist-induced reduction in receptor number involve 
changes in either receptor synthesis and/or receptor lysosomal degradation. Activated 
PAR1 is rapidly phosphorylated and sorted directly to lysosomes and degraded. 
The ability of APC to protect endothelial barrier integrity also involves inhibition of 
thrombin-induced increases in permeability (Feistritzer C. 2005). However, the molecular 
mechanisms through which APC inhibits thrombin-induced increases in permeability are not 
known. In the present study I examined whether exposure of endothelial cells to APC 
desensitizes PAR1 to thrombin signaling. Herein I show that APC promotes protective 
effects in endothelial cells by desensitizing cells to thrombin signaling without affecting 
thrombin-mediated internalization or degradation of PAR1, suggesting a novel mechanism 
of receptor regulation. 
  
 
3.3: Results 
3.3.1: APC desensitizes endothelial cells to thrombin signaling  
To determine how APC prevents thrombin from causing endothelial barrier 
dysfunction we examined whether APC desensitizes cells to thrombin signaling. Thrombin 
caused robust ERK1,2 activation in naïve cells (Fig. 20 A). By contrast, thrombin-stimulated 
ERK1,2 activation was markedly reduced in cells pretreated with APC (Fig. 20 A). 
Moreover, thrombin-induced RhoA activation and p38 kinase activation were considerably 
attenuated in cells pretreated with APC (Fig. 20 B and C), providing further evidence that 
APC desensitizes cells to thrombin signaling to promote endothelial barrier protection. 
Interestingly, inhibition of thrombin-induced ERK1,2 activation by APC required caveolin-1 
expression (Fig. 21), consistent with a critical role for caveolae in APC signaling. Signaling 
by PAR2 agonist peptide, and UTP, an agonist for endogenous purinergic receptors, was 
unperturbed by APC pretreatment, indicating that endothelial cells are generally responsive 
to GPCR activation after APC pretreatment (Fig. 22). 
3.3.2: APC induces PAR1 phosphorylation and does not affect trafficking or 
degradation of the receptor 
We determined whether APC promotes phosphorylation of endogenous PAR1 in 
endothelial cells. Phosphorylated PAR1 was detected after thrombin incubation and 
migrated as a broad band at ~64 kDa (Fig. 23 A and C). Cells exposed to APC also showed 
an increase in PAR1 phosphorylation, which was detected as multiple high molecular 
weight species migrating at and above ~64 kDa (Fig. 23 A). Strikingly, in APC pretreated 
cells, thrombin and APC failed to induce phosphorylation of PAR1 (Fig. 23 A). These data 
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suggest the APC regulates thrombin signaling at the level of the receptor to promote 
endothelial barrier protection.  
In addition to phosphorylation, receptor internalization and lysosomal degradation 
also regulate PAR1
 
signaling (Trejo J. 1999; Trejo J H. S. 1998). We therefore examined 
whether APC affects PAR1 trafficking. Thrombin induced rapid and robust PAR1 
internalization (Fig. 23 B). In contrast, APC failed to promote PAR1 internalization even at 
high concentrations (Fig. 23 B), consistent with retention of PAR1 on the cell surface 
(Schuepbach R.A. 2008). Remarkably, however, thrombin stimulated comparable increases 
in PAR1 internalization in both untreated and APC treated cells (Fig. 23 D), suggesting that 
APC exposure does not prevent thrombin-induced PAR1 internalization.  
We further investigated whether thrombin promotes PAR1 degradation in cells 
exposed to APC. Thrombin caused a shift in mobility and a significant loss of PAR1 protein 
in control cells (Fig. 23 C), consistent with thrombin cleavage and degradation of activated 
PAR1. Activation of PAR1 with the peptide agonist TFLLRNPDNK also decreased receptor 
protein without altering receptor mobility, as expected (Fig. 23 C). To our surprise, 
prolonged exposure to APC failed to induce a significant change in PAR1 mobility or 
amount of receptor protein detected compared to control cells (Fig. 23 C). Moreover, the 
extent of PAR1 degradation induced by thrombin and peptide agonist was comparable in 
APC treated and untreated cells (Fig. 23 C). Together these studies suggest that APC 
desensitizes cells to thrombin signaling by inducing PAR1 phosphorylation, but causes 
limited receptor cleavage and negligible internalization and degradation. 
  
 
3.4: Discussion 
Our studies suggest that APC promotes protective effects by desensitizing endothelial cells 
to thrombin signaling (Fig. 24). We found that APC stimulates PAR1 phosphorylation and 
inhibits thrombin signaling but causes limited receptor cleavage, and negligible 
internalization and degradation. The molecular mechanism by which APC distinctly 
activates PAR1 signaling remains unclear. PAR1 is essential for APC signaling, but 
whether APC induces an active PAR1 conformation similar to thrombin is not known. 
Previous studies have shown that APC has the capacity to cleave PAR1, albeit with 
considerably less efficiency than thrombin (Riewald M. 2002; Ludeman M.J. 2005). 
However, whether APC cleavage of PAR1 is the only critical determinant that facilitates 
PAR1 activation of barrier protective signaling is not known. Thrombin cleaves the majority 
of PAR1, causing a shift in receptor mobility and induces receptor degradation, whereas the 
peptide agonist TFLLRNPNDK promotes PAR1 degradation but not cleavage and hence, 
does not alter receptor mobility. We show here that APC induces PAR1 signaling and 
phosphorylation but causes a minimal change in receptor mobility. Interestingly, we also 
show that prolonged APC incubation does not prevent thrombin-induced PAR1 cleavage, 
internalization or degradation. Thus, in endothelial cells exposed to APC the majority of 
PAR1 is retained on the cell surface and susceptible to thrombin cleavage. Our findings 
raise the intriguing possibility that APC activates a sub-population of PAR1 
compartmentalized in caveolae and stabilizes an active receptor conformation that may be 
distinct from non-caveolar localized activated PAR1. 
How can activation of the same receptor by two different proteases elicit distinct 
cellular responses? If APC activates PAR1 through cleavage and unmasking of the 
tethered ligand like thrombin a similar active receptor conformation would be induced. 
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However, the extent of PAR1 activation by APC would be different from thrombin, which 
efficiently cleaves the receptor (Ludeman M.J. 2005). In this case, we would expect to 
observe quantitative not qualitative differences in signaling. We previously showed that 
PAR1 trafficking is essential for the fidelity of thrombin signaling (Trejo J. 1998; Paing M.M. 
2006). However, in contrast to thrombin, our findings here suggest that APC imparts a 
novel mechanism for regulation of PAR1 signaling that involves receptor phosphorylation 
but not internalization or degradation. Thus, in future pursuits it will be important to 
determine the mechanism(s) by which endothelial cells desensitize and resensitize to APC 
signaling.  
This study has sought to investigate the mechanism by which APC inhibits 
thrombin-mediated PAR1 increase permeability. We asked the question whether APC is 
able to desensitize PAR1 to thrombin signaling. The molecular mechanisms responsible for 
GPCR desensitization have been widely studied for the 2-adrenergic receptor ( 2-AR) 
(Lefkowitz R.J. 1998; Pitcher J.A. 1998). Briefly, GPCRs are initially desensitized by rapid 
phosphorylation of the receptor in the active form by G protein-coupled kinases (GRKs). 
The phosphorylated receptor then binds arrestin, which inhibits interaction with G proteins. 
Arrestin also facilitates GPCR internalization by interacting with clathrin and the adaptor 
protein complex-2 (AP-2), components of the endocytic machinery. Once internalized into 
endosomes, receptor dissociates from the ligand, becomes dephosphorylated, and is then 
recycled back to the plasma membrane ready for activation again. Phosphorylation of 
activated PAR1 initiates rapid desensitization and internalization from the plasma 
membrane. Activated PAR1 is internalized through a dynamin- and clathrin-dependent 
pathway, like many recycling receptors (Trejo J. 2000; Hoxie J.A. 1993). Once internalized, 
PAR1 is sorted away from recycling receptors and targeted to lysosomes for degradation, 
  
 
an event critical for termination of receptor signaling (Trejo J. 1998). Our studies suggest 
that APC promotes protective effects by desensitizing endothelial cells to thrombin 
signaling. Furthermore, we show that APC inhibits thrombin-induced PAR1 phosphorylation 
but not internalization of degradation. Our laboratory demonstrated that, in the absence of -
arrestins, rapid desensitization of PAR1 signaling is markedly impaired while internalization 
remains intact. Thus, internalization is not required for rapid desensitization of PAR1 
signaling by -arrestins. This may suggest a role for -arrestins in APC-mediated PAR1 
desensitization. -arrestin indeed is required for rapid desensitization of PAR1 signaling, 
whereas internalization and lysosomal sorting appear to contribute to termination of PAR1 
signaling observed at later times. Furthermore, most activated GPCRs require 
phosphorylation for -arrestin binding and consequent receptor desensitization. In contrast, 
-arrestins bind to activated PAR1 independent of phosphorylation to promote uncoupling 
from G protein signaling.  
3.5: Material and methods 
Reagents and Antibodies 
Human α-thrombin was purchased from Enzyme Research Laboratories. Human APC was 
from Hematologic Technologies (Essex Junction, VT). The peptides agonists, 
TFLLRNPNDK and SLIGKV were synthesized at the UNC Peptide Facility, Chapel Hill, NC. 
Hirudin and actin antibody were obtained from Sigma (St. Louis, MO). Horseradish 
peroxidase (HRP)-conjugated goat anti-mouse and -rabbit secondary antibodies were from 
Bio-Rad (Richmond, CA). 
[myo-3H]Inositol was purchased from American Radiolabelled Chemicals Inc. Monoclonal 
anti–phospho-p44/42 mitogen-activated protein kinase (MAPK); extracellular signal- 
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regulated kinase (ERK 1,2) antibody and polyclonal anti–p44/42 MAPK (ERK1,2) antibody 
were from Cell Signaling Technology, Inc. (Beverly, MA). Anti-phospho-p38 and anti-p38 
were from Cell Signaling Technology, Inc. (Beverly, MA). Anti-actin antibody was purchased 
from Sigma-Aldrich. Anti-RhoA was from Santa Cruz Biotech. Horseradish peroxidase-
conjugated goat anti-mouse and anti-rabbit secondary antibodies were from Bio-Rad 
(Richmond, CA).  
 
Cell lines 
EA.hy926 cells were obtained from Coragene Edgell (UNC-Chapel Hill). Cells were 
manteined in DMEM plus 10 % FBS and passaged once a week. 
 
EA.hy926 cells expressing PAR1 shRNA or CAV1 shRNA 
The short hairpin RNAi (shRNA) 5’- AGAUUAGUCUCCAUCAAUA-3’ targeting PAR1 and 
non-specific siRNA 5’-CUACGUCCAGGAGCGCACC-3’ were subcloned into pSilencer 5.1-
U6 Retro (Ambion, Austin, TX) as described (Coughlin S.R. 2005). The caveolin-1 shRNA 
(5’-AAGATGTGATTGCAGAACCAGA-3’) construct in pRVH1-puro was obtained from K. 
Simons and scrambled shRNA 5' –GTAAATGCCATACCTTATA-3' of PAR1 siRNA 
sequence was inserted into pSUPER.retro.puro vector (Oligoengine, Seattle, WA). 
Retroviruses were generated using PA317 packaging cells and used to infect EA.hy926 
cells. Mass populations of cells stably transduced with PAR1 shRNA, caveolin-1 shRNA, 
non-specific, scrambled shRNAs and vector control constructs were selected with 0.6 µg/ml 
of puromycin.  
 
RhoA Activity Assay  
  
 
GST-rhotekin RBD was purified and assays were conducted as described below. EA.hy926 
endothelial cells were plated in 6-well dishes at 5 X 105 cells per well, grown for two days, 
deprived of serum and then treated with or without agonists for various times at 37°C. To 
assess RhoA activation, cells were lysed in buffer containing 50 mM Tris-HCL, pH 7.6, 500 
mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 20 mM MgCl2 with protease 
inhibitors. Endogenous RhoA activity was then measured in pull-down assays using a GST 
fusion of the Rho binding domain (RBD) of Rhotekin. The GST PAK-PBD fusion constructs 
were transformed into BL21 (DE3) E. coli and fusion proteins were induced and prepared 
using standard techniques. Rhotekin-RBD (90 mg) bound to glutathione-Sepharose beads 
were then incubated with cell lysates for 1 h at 4°C an d washed. GTP-bound RhoA was 
eluted in 2X SDS-sample buffer containing 100 mM Tris-HCl, pH 6.8, 20% glycerol, 4% 
SDS, 0.02% bromophenol blue, resolved by SDS-PAGE and transferred to membranes. 
The amount of endogenous activated RhoA was then detected by immunoblotting using a 
monoclonal anti-RhoA antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Immunoblots 
were developed with enhanced chemiluminescence (ECL) (Amersham Biosciences, Inc., 
Arlington, IL), imaged by autoradiography, and quantitated using a Bio-Rad Fluor-S- 
MultiImager (Richmond, CA). 
 
ERK1,2 and p38 activation 
EA.hy926 cells were plated in 24-well dishes at a density of 0.7x 105 per well. Cells were 
serum-starved in 0.2% FBS over-night. The cells were pre-incubated in the absence of 
serum for 2 hrs and then treated with 10nM thrombin or 5 nM APC plus 0.5U/ml of Hirudin 
or left untreated. Then the cells were lysed in 2x SDS-gel loading buffer [100 mmol/L Tris-
HCl (pH 6.8), 20% glycerol, 4% SDS, 0.02% bromophenol blue]. Cell lysates were resolved 
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by SDS-PAGE, transferred to membranes, and immunoblotted with an anti–phospho-
p44/42 MAPK (ERK1,2) or anti-phospho p38 antibodies (Cell Signaling). To detect total 
p44/42 MAPK (ERK1,2), membranes were stripped and reprobed with an anti–p44/42 
MAPK (ERK1,2) or anti p38 antibodies. Immunoblots were developed, imaged, and 
quantitated using a Bio-Rad Fluor-S MultiImager. 
 
Cell Surface ELISA 
EA.hy926 cells were plated at 0.7 X 105 cells per well in 24-well culture dishes. After 
incubations, cells were fixed and processed as previously described  (Paing M.M., 2002). 
The amount of PAR1 remaining on the cell surface was detected using a rabbit polyclonal 
anti-PAR1 antibody generated against the hirudin-like domain as previously described (34, 
38). The amount of EPCR on the cell surface was quantitated using a monoclonal anti-
EPCR JRK 1500 antibody generously provided by C. Esmon (Oklahoma Medical Research 
Foundation, Oklahoma City, OK).  
 
PAR1 Phosphorylation and Degradation 
EA.hy926 cells plated at 5 X 105 cells per well in 6-well dishes were grown overnight 
and PAR1 degradation was determined as described (Paing M.M., 2002). To assess PAR1 
phosphorylation, EA.hy926 cells were labeled with 200 ¼Ci [32P]orthophosphate (Perkin-
Elmer Inc., Boston, MA) in phosphate-free DMEM containing 1 mg/ml BSA for 3 h at 37°C. 
After cell treatments, PAR1 was immunoprecipitated with anti-PAR1 WEDE-15 monoclonal 
antibody, resolved by SDS-PAGE and transferred to membranes. Phosphorylated receptor 
was detected by autoradiography. The amount of PAR1 in immunoprecipitates was 
determined by immunoblotting with polyclonal anti-PAR1 antibody. 
  
 
Data Analysis 
Data were analyzed using Prism 4.0 software (GraphPad), and statistical significance was 
determined using InStat 3.0 (GraphPad). Group comparisons were made using an unpaired 
t-test.  
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Fig. 20. APC desensitizes PAR1 to thrombin signaling. (A) EA.hy926 cells were 
preincubated with or without 10 nM APC for 1 h at 37°C and then stimulated with thrombin 
(Th) or APC at 37°C and ERK1,2 activation was examine d by immunoblotting. The data 
(mean ± S.E.) are expressed as the fold-increase over untreated control and are the 
averages of three separate experiments. The difference between thrombin-induced ERK1,2 
activation in untreated versus APC pretreated cells was significant (*, P < 0.05). (B) Serum-
deprived endothelial cells were pretreated with 10 nM APC (with 0.5 U/ml hirudin) for 1 h at 
37°C, washed and then incubated in the absence or presen ce of various concentrations of 
thrombin (Th) or APC (0.5 U/ml hirudin) for 5 min at 37°C. Cells were lysed and the 
activation of p38 kinase was determined using anti-phospho-p38 antibodies. Membranes 
were stripped and re-probed with anti-p38 antibody to control for loading. The data (mean ± 
S.E.) shown are expressed as the fold-increase over control and are the averages of three 
independent experiments. (C) Endothelial cells were preincubated with or without 10 nM 
APC for 1 h at 37°C and then stimulated with thrombi n (Th) or APC at 37°C and activation 
of RhoA was determined. Similar findings were observed in two independent experiments.  
  
 
 
 
 
 
Fig. 21. APC desensitization of PAR1 to thrombin signaling is caveolin-1 dependent. 
Control and caveolin-1 (CAV1) deficient cells were preincubated with 10 nM APC for 1 h at 
37°C and then stimulated with or without 10 nM thro mbin (Th) at 37°C and ERK1,2 
activation was determined. The difference between desensitization induced by APC in 
control versus Caveolin-1 deficient cells was significant (*, P<0.05). 
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Fig. 22. APC does not inhibit GPCRs activation through a general mechanism. Pre-
incubation with APC for 3 hrs does not inhibit PAR2 nor UTP signaling to calcium 
mobilization. 
  
 
 
Fig. 23. APC stimulates PAR1 phosphorylation but does not stimulate PAR1 
internalization or degradation. (A) EA.hy926 cells labeled with [32P]orthophosphate were 
preincubated with or without 10 nM APC for 3 h at 37°C and then stimulated with 10 nM Th 
or 10 nM APC for 3 min at 37°C. Immunoprecipitated 32P-labeled PAR1 was detected as 
described (21). Similar results were observed in three independent experiments. (B) Cells 
were incubated in the absence or presence of thrombin (Th) or APC for various times at 
37°C and the amount of PAR1 remaining on the cell su rface was quantitated by ELISA. The 
data (mean ± S.D., n=3) are representative of three independent experiments. The 
difference between thrombin and untreated control at various times was significant (*, 
P<0.05). (C) Cells pretreated with or without 10 nM APC for 3 h at 37°C, and then 
incubated with 10 nM thrombin (Th), 10 nM APC or 100 µM TFLLRNPNDK for 90 min at 
37°C and the amount of PAR1 was determined as described  . The asterisk indicates 
detection of the heavy and light chains of the immunoprecipitating antibodies. Data (mean ± 
S.E.) are expressed as the fraction of PAR1 protein remaining compared to untreated 
control and are the averages of three independent experiments. A significant difference (*, 
P<0.05 or **, P<0.01) was detected between agonist-treated versus untreated control in 
some cases. (D) Cells were preincubated with or without 10 nM APC for 3 h at 37°C, and 
processed as in B). The data (mean ± S.D., n=3) are from one representative experiment. 
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Fig. 24. Model of APC-induced PAR1 desensitization. When activated by thrombin 
PAR1 is rapidly desensitized and later the signal is terminated by internalization and 
degradation. Activated by APC, PAR1 is desensitizes but not internalized nor degraded. 
  
 
CHAPTER4: RATIONALLY DESIGNERTIFICIAL TRANSCRIPTION FACTORS ARE 
ABLE TO REPROGRAM METASTATIC CANCER CELLS 
4.1: Abstract 
The serine protease inhibitor maspin is an atypical member of the family of serine 
protease inhibitors. Maspin inhibits the serine-protease urokinase plasminogen activator 
(uPA) in vitro and in vivo. Maspin has potent tumor suppression functions in vitro and in 
vivo. Interestingly, the maspin promoter is silenced by epigenetic and transcriptional 
mechanisms in cancer cells. In the third chapter of my dissertation I developed an inducible 
system to express artificial transcription factors (ATFs) that are able to re-activate maspin 
promoter in a mouse model. I show that re-expression of maspin by ATFs leads to 
reduction of tumor growth and metastasis formation in an in vivo xenograft animal model.  
4.2: Introduction 
Metastatis is the leading cause of deaths of breast cancer patients. The metastatic 
process involves several steps including invasion, intravasation, extravasation and growth 
at a secondary site. Mammary serine protease inhibitor (maspin) is a tumor suppressor 
affecting multiple processes involved in neoplastic progression. Importantly, maspin is 
silenced in aggressive epithelial tumors by epigenetic and transcriptional mechanisms 
(Futscher B.W. 2004). Ectopic expression of maspin cDNA is associated with primary tumor 
growth reduction (Zhou Z. 1994), decreased angiogenesis (Zhang M. 2000), and reduction 
of tumor invasion and metastasis (Sheng S. 2004; (Shaefer J.S. 2003). Our laboratory has 
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previously characterized artificial transcription factors (ATFs) able to re-activate maspin in 
invasive breast cancer cell lines (Beltran A. 2007). ATFs are composed of sequence-
specific zinc finger (ZF) domains to specifically target endogenous genes. The ZF domains 
are linked to the VP64 activator domain, which mediates up-regulation of the target genes. 
Among all the ATFs constructed, ATF-126 was the most efficient in up-regulating the 
maspin promoter in invasive breast cancer cells. Furthermore, ATF-126-mediated 
reactivation of maspin has been shown to inhibit primary tumor formation (Beltran A. 2007). 
In this study I address the therapeutic potential of ATF-126 to inhibit tumor growth and 
metastatic colonization using a xenograft animal model. The reactivation of maspin causes 
a concomitant induction of selective tumor-cell apoptosis, which complicates the study of 
the effect of ATF on pre-existing tumors. Therefore, I generated an inducible Tet-on 
retroviral expression system in order to control the expression of the ATFs in vivo. We show 
that the ATF-126 is able to reduce tumor growth and metastasis formation in an in vivo 
xenograft mouse model. Fig. 25 illustrates the overall strategy of this study. 
4.3: Results 
4.3.1: Inducible expression of the artificial transcription factor ATF-126 results in 
apoptosis of invasive breast cancer cell lines.  
A human invasive MDA-MB-231 breast cancer cell line stably expressing a Tet On-
regulated ATF-126 was generated. Briefly, the ATF-126 cloned in the retroviral expression 
vector p-RetroX-Tight-Pur under the control of a tetracycline operator sequence (tetO) and 
vector controls were retroviral transduced in MDA-MD-231 cell line together with the Retro-
Tet-on-Advance vector which constitutively expresses the tetracycline-controlled trans-
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activator. The trans-activator binds tetO in the presence of doxycycline (Dox) and drives the 
transcription of the gene of interest.  
The inducible tet-on-regulated was first validated in MDA-MB-231 cells in vitro. The 
expression of ATF and maspin mRNA were assessed in the presence or absence of 
doxycycline by real-time polymerase chain reaction (RT-PCR). The ATF and maspin were 
higly expressed in the presence of doxycycline (Fig. 26 A and B). Protein levels of both, the 
ATF and maspin have been assessed by immunoprecipitation followed by immunoblot (Fig. 
27 A and B) using an HA antibody for the detection of ATF or maspin specific antibody for 
the detection of maspin. The ATF and maspin mRNA and protein expression was detected 
only in presence of Dox. We also have assessed maspin mRNA expression after treatment 
with doxycycline and subsequent removal of the drug. We have shown that after removal of 
Dox the level of maspin returns to normal levels suggesting that the ATF action is reversible 
(Fig. 26 C). 
Second, we evaluated the capability of the ATF to induce early apoptosis by 
performing annexin staining in presence and absence of Dox. We found that only ATF-126 
and not inactive variants of this ATF such as NOVP64 (which lacks the activator domain) 
effectively induced apoptosis in the breast cancer cells upon Dox treatment (Fig. 28 A and 
C). To assess whether the apoptotic phenotype was due to ATF’s effect on maspin rather 
than off targets we further transduced MDA-MB-231 expressing the ATF-126 under control 
of doxycycline with shRNA targeting maspin or scramble shRNA. I first validated that the 
presence of maspin shRNA results in loss of maspin mRNA (Fig. 28 B). With this approach 
I demonstrated that in the presence of shRNA targeting maspin the apoptotic phenotype 
due to ATF-126 was rescued (Fig. 28D). This suggests that maspin up-regulation is 
responsible for the apoptotic phenotype. 
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4.3.2: To study the capability of ATFs to reduce tumor growth and metastasis in an 
immunodeficient mouse model (SCID). 
To assess the effect of ATF-126 on pre-existing tumor and metastasis formation we 
transduced MDA-MB-231 cells stably expressing the Tet-on system for the ATF-126 with a 
luciferase retroviral vector. This luciferase vector allowed us to track tumor cells in vivo by 
monitoring luciferase activity by bioluminescence imaging (BLI). I implanted the MDA-MB-
231 cells stably expressing both the Tet-on system for the ATF-126 and the luciferase 
retroviral vector subcutaneously in the flank of SCID mice. The MDA-MB-231 cells stably 
expressing the Tet-on system empty vector were used as control. Primary tumor formation 
over time was then followed by BLI. Tumor growth was also followed by caliper 
measurements and represented as tumor volume (mm3). When the tumors reached 0.5 cm 
of diameter the mice were fed with doxycycline and primary tumors volume were measured 
over time. In mice injected with MDA-MB-231-ATF-126-Luc the tumor volume was 
significantly reduced upon treatement with doxycycline (Fig. 29 C and D) compared to 
control (Fig. A and B). Hematoxyllin-eosin staining of the tumors extracted from the mice 
also showed that induction of ATF-126 results in reduction of blood vessel number (Fig. 30 
A). The data were quantified by counting the number of vessels from 2 different animals 
using light microscopy (Fig. 30 B). To assess whether ATF-126 expression could also block 
metastasis formation, mice were injected via tail vein with MDA-MB-231 cells stably 
expressing the inducible ATF-126 or the control empty vector plus a luciferase retroviral 
vector. Tumor cell metastasis to the lungs was then assessed by BLI (Fig. 31). I show that 
induction of ATF-126 expression following Dox administration totally abolishes metastatic 
colonization.  
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4.4 Discussion 
In this study I used artificial transcription factors to up-regulate the tumor suppressor 
maspin in vivo. I developed an inducible retroviral vector system for the controlled 
expression of ATF-126. I validated this approach by assessing up-regulation of maspin and 
ATF-126 re-expression in a doxycycline dependent manner. I demonstrated that maspin 
up-regulation is responsible for the apoptotic phenotype in breast cancer cells. We also 
have shown that after doxycycline removal the level of maspin returns to normal suggesting 
that the ATF action is reversible. We have shown that subcutaneous implantation of MDA-
MB-231 breast cancer cells stably expressing ATF-126 under Dox control and also 
expressing luciferase, leads to tumor volume reduction and inhibition of metastasis 
formation. These results prove that ATF-126 has a potent therapeutic potential for breast 
cancer.  
4.5: Materials and Methods  
Development of a Double Stable Tet-On Advanced Cell Line for ATF-126 
The Artificial Transcription Factors (ATFs) was delivered into the cells by retroviral 
tranduction. Briefly, gagpol packaging cells (3 x 105 cells/ml) were seeded on 10 cm plates 
coated with 100 µg/ml Poly-D-Lysine solution. Gagpol cells were then incubated at 37 °C, 
5% CO2 overnight. After 16 hrs the gagpol cells were transfected with pMDG.1 (VSV G-
envelope-expressing plasmid) and the retrovirus vector pTight maspin specific ATFs or 
empty using Lipofectamin system. Another set of gagpols were transfected with pMDG.1 
and the transactivator vector pAdvance. Gagpol cells were incubated for 3-hr at 37 °C, 5% 
CO2. After 3hrs, the transfection media was substituted with DMEM supplemented with 
10% FBS. The plates were then incubated for 48-hr at 37 °C, 5% CO 2. The host cells were 
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seeded 24 hr before harvesting the retrovirus at a seeding density of 1 x 105 cells/plate in a 
10 cm plate. 48hrs after transfection the gagpol supernatant containing the retrovirus was 
collected and filtered with a 0.22-m filter unit to eliminate any cell debris (residual packaging 
cells). The pAdvaced retrovirus and the pTight-ATF retrovirus were combined in a 1:1 ratio. 
10 µl/ml of Polybrene was added to the virus-containing media to a final concentration of 8 
µg/ml. Double retrovirus-containing media was added to each host cell plate (e.g. MDA-MB-
231) and incubated for 6-8 hr at 37 °C, 5% CO 2. Fresh media was added to the gagpol cells 
to allow more virus production. The retrovirus collected was added to the host cells every 8 
hr for a total of four times. The day after the end of the last infection the retrovirus-
containing media was removed from the host cells and fresh media was added to the host 
cells.  
 
Immunoprecipitation and immunoblot 
Cells were plated at 3.5 x 105 cells in 10 cm plates and 3 plates for condition were used. 
The cells were plated in the absence or presence of 100ng/ml Dox and incubated for 72 
hrs. The cells were then lysed on ice using RIPA buffer (Pierce) plus protease inhibitors. 
After all cells were lysed, solubilization continued by rotating tubes for 1 hr at 4°C. The cells 
were spinned at 14,000 rpm for 20 min at 4°C. Protein concentration was determined by 
Bradford protein assay. Primary antibody (anti-maspin T50, Cell signaling or anti-HA from 
Covance) was added to the cell lysates incubate with gentle rocking overnight at 4°C. 
Protein A/G plus beads (Pierce) (20 µl of 50% bead slurry) were added and incubated with 
gentle rocking for 2 hours at 4°C. Lysated were then microcentrifuged for 30 seconds at 
4°C at 2000 g and pellets washed 3 times with 500 µl o f 1X cell lysis buffer and 1x with 
PBS. The pellets were risuspended with 20 µl 3X SDS sample buffer and heated to 95–
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100°C for 3 minutes, then microcentrifuged for 1 minu te at 14,000 X g and loaded on SDS-
PAGE gel (pre-cast gels 10% from Invitrogen). The proteins were transferred on pvdf 
membrane and analysed by Western blotting using anti-maspin antibody (BD) or anti-HA 
antibody. 
 
Real-time quantitative PCR  
RNA was isolated from ATF-transduced and control cells using a commercial RNA 
extraction system (Qiagen's RNeasy Plus Mini kit, cat. no. 74134), following the 
manufacturers' instructions precisely. cDNA was then synthesized from RNA using the 
High-Capacity cDNA Archive Kit (Applied Biosystems) and following the manufacturers' 
instructions. RT-PCR reaction was performed using TaqMan system from Applied 
Biosystems.  3 PCR replicates for each cDNA sample were performed.  
Briefly; 10 µl of 2X Fast Taqman, 1 µl of Primers/Probe mix 20X and 4 µl of 
Nuclease-free Water were used per reaction. 100 ng of cDNA in 5 µl were placed into 0.2 
ml PCR tube. 15 µl of master mix were added into each tube. 
The plate was plated into the real-time PCR machine. The PCR conditions were: 10 min at 
95 °C, and 30 sec at 65 °C for 40 cycles. The data were analyzed using comparative CT 
method (2-∆∆CT method).  
 
Analysis of apoptosis by Annexin V staining 
During early stages of apoptosis the phospholipid phosphatidylserine (PS) is 
exposed to the external cellular environment. Annexin V is a phospholipid-binding protein 
that has a high affinity for PS, and binds extracellular PS. The Annexin V protein conjugated 
with Phycoerythrin (PE) is used to quantify the early apoptotic effect of maspin-specific 
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ATFs in cancer cells. In addition, the 7-Amino-actinomycin D (7-ADD) is use to discriminate 
between live and dead cells. 7-AAD intercalates into double-stranded nucleic acids of dead 
or dying cells, but is excluded by viable cells. Briefly, cells were washed twice with cold 
PBS and resuspend in 1X Binding Buffer at a concentration of 1x106 cells/ml. 100 µl of the 
cell suspension (1x105 cells) were transferred into a 5 ml culture tube. 5 µl of PE-Annexin V 
and/or 5 µl of 7-AAD were added. The cells were gently vortexed and incubated for 15 min 
at RT (25 °C) in the dark. 400 µl of 1X binding buffer was added into each tube. Apoptosis 
was then quantified by flow cytometry within one hour. The percentage of apoptosis is 
measured by flow cytometry using a FACS Calibur and CellQuest software. 
 
Subcutaneous Injections  
Cancer cells expressing the inducible ATF-126 or the control empty vector will be 
transduced with retrovirus expressing a Luciferase marker (pLXN-Luci). Approximately 106 
cells were collected and re-suspended with matrigel (BD bioscience) 1:1 volume ratio in a 
total volume of 200 µl. The cells-Matrigel mixture, kept on ice, will be injected into the 
mouse flank subcutaneously using syringe with a needle of size 21-25G. Tumor growth has 
been monitored by caliper twice a week. When the tumor reached a size of approximately 
0.5 cm deoxycycline was administered to mice to induce the expression of the ATF. 
Deoxycycline was given in form of green food pellet with a concentration of 200 mg of 
deoxycycline per Kg of mice chow for a period of 15-30 days. During the entire experiment 
the mice weight was monitored to verify whether toxicity occurred. Tumor volume was 
monitored by caliper and Bioluminescence imaging (BLI). Approximately days after 
doxycycline treatment the mice were sacrificed by CO2 plus cervical dislocation. After death 
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the tumors were extracted from control and ATF-induced animals and fixed in 10% buffered 
formalin for immunohistochemistry analysis. 
 
Tail-vein 
Three days before the injections the mice are kept in normal or doxycycline diet. 
Right before injections the animal is placed into a plastic mouse restraint so that the animal 
is not freely mobile, but its tail is able to be handled. Its tail is place into warm water so that 
the tail vein is more visible. Alternatively a heat lamp may be used. Once the animal’s tail is 
warmed to adequate temperature then it is ready for the procedure. The tail is wiped with 
alcohol to sterilize the area to be injected. 1x106 double stable cell lines for ATF-126 or 
empty vector are injected per animal in a total volume of 200ul using a 27 gauge needle 
syringe. The animal is monitored during the procedure by observing its respiratory rate. 
After the procedure is done the animal is monitored to make sure it is not stressed and 
returns back to its normal respiratory rate, if elevated. The cells injected also express 
luciferase that allows monitoring metastasis formation into the lung by Bioluminescence 
imaging (BLI) once a week for 20 days. The mice were then sacrificed by CO2 plus cervical 
dislocation. After death the lungs were extracted from control and ATF-induced animals and 
fixed in 10% buffered formalin for quantification of metastasis. 
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Fig. 25 Strategy for inducing ATF expression in tumor cells and implantation in SCID 
mice.  The ATF was cloned into pRetroX-Tight inducible system. MDA-MB-231-Luc cells 
were retrovirally transduced with the clone. The ATF-transduced MDA-MB-231-Luc cells 
were implanted in SCID mice. 
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Fig. 26. ATF and maspin mRNA are expressed in the presence of doxycycline (Dox). 
(A) ATF mRNA up-regulation was assessed by RT-PCR using primers targeting the 
activator domain with and without Dox 100ng/ml for 72hrs in MDA-MB-231 non infected cell 
line, MDA-MB-231 plus NOVP64 which is the 6 zinc-fingers without the activator domain, 
the control empty vector and MDA-MB-231 plus ATF-126. (B) Maspin mRNA up-regulation 
was assessed by RT-PCR with and without Dox 100ng/ml for 72hrs. (C) Maspin mRNA up-
regulation was assessed by RT-PCR with and without Dox 100ng/ml for 72hrs and after 
removal of Dox and recovery of the cells. 
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Fig. 27. Expression of ATF and maspin protein. (A). ATF protein up-regulation was 
measured by immunoprecipitation of the ATF using an anti-HA antibody followed by 
immunoblot. (B). Maspin protein up-regulation was measured by immunoprecipitation of 
maspin from total lysates using an anti-maspin antibody followed by immunoblot with 
maspin antibody. 
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Fig. 28. Expression of ATF-126 induces apoptosis and maspin shRNA rescues the 
apoptotic phenotype. (A). MDA-MB-231 treated with Dox (100ng/ml) for 72 hrs present 
cell death. (B) Loss of expression of maspin mRNA in the presence of maspin shRNA 
compared to scrambled. (C). Quantification of ATF-126-induced apoptosis by Annexin V 
staining after 72 hrs of Dox (100ng/ml).  (D). Rescue of apoptotic phenotype in the 
presence of maspin shRNA compared to scrambled.  
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Fig. 29. ATF-126 expression reduces primary tumor volume. (A). Bioluminescence 
imaging of mice injected with control empty vector -/+ Dox. (B). Quantification of tumor 
volume measurement by caliper of n=3 mice per group. (C). Bioluminescence imaging of 
mice injected with ATF-126 -/+ Dox. The figure also shows a mouse that has been removed 
from Dox diet and put on normal diet. (D). Quantification of tumor volume measurement by 
caliper of n=4 mice injected with ATF-126 and n=4 mice injected with ATF-126 and treated 
with Dox (there is no quantification for the Dox removal condition). 
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Fig. 30. ATF-126 expression reduces blood vessels number. (A). Hematoxylin-eosin 
staining of sections of tumors extracted from ATF-126 and ATF-126 + Dox. (B). 
Quantification of blood vessels number normalized by area in ATF-126 and ATF-126 + Dox 
treated mice.  
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Fig. 31. ATF-126 expression blocks metastasis formation. (A). Bioluminescence 
imaging of mice injected via tail vein with control empty vector -/+ Dox or ATF-126 -/+Dox to 
assess metastasis to the lungs.  
 
 
 
 
 
 
  
CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
The work presented in this dissertation has demonstrated that different proteases 
can signal through the same receptor to elicit differential cellular responses. I also showed 
that a protease inhibitor implicated in tumor progression can be regulated by an inducible 
artificial transcription factor (ATF) indicating a potential use of ATFs as a therapeutic 
agents. 
In chapter 2, I show that endogenous PAR1 is required for thrombin and APC 
signaling in endothelial cells. I further demonstrate that caveolin-1 is essential for activation 
of PAR1 signaling by APC but not thrombin, indicating that caveolae are critical for 
protease-selective signaling by PAR1. Specifically, to investigate how PAR1 signals when 
activated by APC in endothelial cells I assessed activation of the small GTPases RhoA and 
Rac1. Thrombin cleaves PAR1 and in turn, PAR1 activates RhoA. Conversely, I show that 
APC activates PAR1 to stimulate Rac1 but not RhoA signaling. I further show that caveolin-
1 is essential for APC induced Rac1 activation. To determine whether caveolin-1 is also 
required to promote APC-mediated endothelial barrier protective effects we assessed 
endothelial permeability in the presence or absence of shRNA targeting caveolin-1. We 
show that caveolin-1 knock-down abolished APC-mediated protective effects on endothelial 
permeability.  
Evidence presented here suggests that compartmentalization of PAR1 in caveolae 
facilitates selective endothelial barrier protective signaling. The molecular determinants that 
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specify the targeting of PAR1 and signaling components to caveolae have not been 
established but may involve post-translational modifications. A large number of GPCRs 
appear to be modified by palmitoylation, which occurs through the covalent attachment of a 
C16 fatty-acid chain to cysteine residues localized within the cytoplasmic tail of the receptor 
PAR1 has cytoplasmic cysteine residues that could serve as sites for palmitoylation but this 
has not been investigated. Previous studies have shown that palmitoylation of tissue factor 
(TF) facilitates its localization to caveolae and prevents protein kinase C dependent 
phosphorylation, a process that controls tissue factor pro-coagulant activity (Dorfleutner A. 
and Ruf W. 2003). Thus, the modulation of TF with palmitoylation may facilitate localization 
of TF-FVIIa and Xa with PAR2 in caveolar microdomains to promote cellular signaling. 
Interestingly, several studies suggest that protein palmitoylation protects proteins from 
ubiquitination and subsequent degradation (Valdez-Taubas J. 2005; Abrami L. 2006). 
Modification of proteins with ubiquitin occurs through the covalent attachment of ubiquitin, a 
76-amino acid protein, to lysine residues on the target protein. PAR1 is ubiquitinated (Wolfe 
B.L. 2007; Jacob C. 2005), but whether PAR1 ubiquitination facilitates receptor 
palmitoylation and/or targeting of proteins to caveolae has not been examined. To address 
this possibility a mutant form of PAR1 can be generated where the cytoplasmic cysteine 
residues are replaced with alanine residues. Endothelial cells expressing shRNA targeting 
PAR1 and therefore PAR1 deficient can then be transfected with the mutant or the wild-type 
forms of PAR1 and then Rac1 activation by APC can be assessed to verify whether APC 
signaling to caveolae depends on PAR1 palmitoylation sites. Furthermore, these mutants 
can be used to assess PAR1 localization into caveolae by performing a subcellular 
fractionation in a sucrose gradient. We expect that the expression of the palmitoylation 
 88 
 
deficient PAR1 will abolish APC signaling to Rac1 and also will affect PAR1 localization to 
caveolae. 
By bioinformatic analysis we have also found that both EPCR and PAR1 contain 
caveolin-1 binding motifs. The caveolin-1 binding motifs, reported in the literature, are 
ΦXΦXXXXΦ or ΦXXXXΦXXΦ or the combined motif ΦXΦXXXXΦXXΦ where Φ is any 
aromatic amino acid (tryptophan/W, phenylalanine/F or tyrosine/Y) (Couet J. 1997; Liu P. 
2002). EPCR contains the following caveolin-1 binding motif: Y35-F-R-D-P-Y-H-V-W43 
whereas PAR1 contains two caveolin-1 binding motifs: Y161-Y-F-S-G-S-D-W168 and Y267-A-
Y-Y-F-S-A-F274. The latter motif is more likely to bind caveolin-1 since is situated in the 
region of fifth transmembrane domain whereas the other motif, which is extracellular 
probably does not. Indeed, it has been reported in the literature that the hedgehog receptor 
patched interacts with caveolin-1 through a caveolin-1-binding motif located in the region of 
its seventh transmembrane domain (Karpen H.E. 2001). To investigate caveolin-1 
interactions with EPCR and/or PAR1, the caveolin-1 binding motifs on EPCR and/or PAR1 
can be mutated by replacing the aromatic amino acids with alanines and localization of 
PAR1 and EPCR into caveolae can be assessed by subcellular fractionation in a sucrose 
gradient.  
Endothelial permeability is induced by invasive cancer cells which secrete VEGF 
and other factors to increase the leakiness of blood vessels. However, whether APC inhibits 
thrombin induced PAR1-mediated cancer progression has not been examined. Recently 
Bezuhly M et al. demonstrated that APC inhibits tumor cell metastasis (Bezuhly M. 2009). 
However, whether APC prevents thrombin ability to promote tumor progression has not 
been determined. APC also inhibits VEGF-induced increase in endothelial cell permeability 
(Feistritzer C. 2005) which suggests that APC may play an important role in inhibiting 
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tumor-induced vascular leakiness. To test this hypothesis a trans-endothelial migration 
assay can be performed in a double chamber system. Endothelial cells would be seeded in 
the upper chamber and checked for monolayer formation. The endothelial cells will be first 
treated with thrombin and then invasive breast cancer cells loaded with a florescent dye will 
be added on top of the endothelial monolayer. Migration of the cancer cells through the 
endothelium can then be followed by fluorescent microscopy. Briefly the upper chamber will 
be cleaned and non-migrating cancer cells as well as endothelial cells were removed. 
Fluorescence at the bottom of the chamber will be assessed. I expect that thrombin 
treatment will enhance breast cancer cells migration through the monolayer. To test the 
hypothesis that APC inhibits thrombin induced breast cancer cells migration, the endothelial 
cells seeded in the upper chamber will be first pre-treated with APC and then treated with 
thrombin. The breast cancer cells will be plated on top of endothelial cells as described 
above and number of fluorescent cells migrated will be assessed by microscopy and 
quantified. I expect that pre-treatment with APC will block thrombin-induced cancer cells 
migration through the endothelial monolayer. 
In chapter 3 I determined that APC desensitizes PAR1 to thrombin signaling by 
inhibiting thrombin-induced activation of ERK1/2, p38 and RhoA signaling. Interestingly, I 
also found that APC stimulates PAR1 phosphorylation but causes limited receptor 
internalization and degradation. Strikingly, APC does not prevent thrombin-induced PAR1 
cleavage, internalization or degradation. Thus, in endothelial cells exposed to APC the 
majority of PAR1 is retained on the cell surface and susceptible to thrombin cleavage. Our 
findings here suggest that APC imparts a novel mechanism for regulation of PAR1 signaling 
that involves receptor phosphorylation but not internalization or degradation. The 
desensitization of PAR1 signaling is controlled by agonist-induced PAR1 phosphorylation 
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and the interaction with β-arrestin. PAR1 internalization and lysosomal degradation are also 
critical for termination of receptor signaling (Paing M.M. 2002). Interestingly, activated 
PAR1 internalization occurs independently of arrestins (Chen C.H. 2004). Here I found that 
APC induces desensitization but does not affect internalization or degradation of the 
receptor suggesting that β-arrestin may be involved in this process. This possibility can be 
evaluated using siRNA technology and assessing APC-induced PAR1 desensitization in β-
arrestin knock-down background. 
In chapter 4 I developed an inducible retroviral vector system for the controlled 
expression of ATF-126. I validated this approach by assessing up-regulation of maspin and 
ATF-126 re-expression in a doxycycline dependent manner. I demonstrated that maspin 
up-regulation is responsible for the apoptotic phenotype in breast cancer cells. I also have 
shown that after doxycycline removal the level of maspin returns to normal levels 
suggesting that the ATF action is reversible. I have shown that subcutaneous implantation 
of MDA-MB-231 breast carcinoma cells stably expressing ATF-126 under Dox control leads 
to tumor volume reduction and inhibition of metastasis formation. Further experiments will 
elucidate the mechanism through which ATF-126 exerts its anti-cancer action. This can be 
addressed through genome wide array technology. The genome array will allow 
identification of genes regulated by ATF-126. Preliminary data I have obtained show that 
genes responsible for mesenchymal to epithelial transition (MET) such as E-cadherin and 
claudins are up-regulated, suggesting that this cancer cells are re-programmed toward a 
more epithelial-cell like phenotype. Genes involved in apoptosis and senescence are also 
found up-regulated, whereas genes involved in mitosis are down-regulated. This may 
suggest a mechanism by which ATF-126 may exert an apoptotic effect in cancer cells but 
not in normal cells (Beltran A. 2007 ). A detailed kinetic analysis also will be performed to 
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assess which genes are early regulated by ATF-126 expression. This will help to uncover 
the overall signaling pathway regulated by ATF-126. Furthermore we can use shRNA 
targeting maspin to address whether the genes regulated require maspin expression or 
whether they are a result of ATF-126 function and its potential off-target effects. Another 
important method to fully understand the ATF-126 function is to determine the ATF-126 
binding sites within genomic DNA. To address ATF-126 specificity a Chromatin 
Immunoprecipitation-Sequencing (ChIP-Seq) assay will be performed. It has previously 
been shown in our lab that ATFs synergies with chromatin remodeling drugs enhancing the 
ATF-effects in vitro. Therefore, we sought to validate in vivo that the effect of ATFs can be 
potentiated using chromatin remodeling drugs in concomitance. For this purpose a 
xenograft model can be established in which mice will be kept in the absence of Dox and 
MDA-MB-231-luc transduced with ATF-126 under Dox control will be implanted 
subcutaneously. After the tumor reaches a visible size Dox will be administered in the 
presence or absence of chromatin remodeling drugs and tumor growth assessed by BLI 
and caliper measurements. Further studies will be oriented towards the development of 
advanced delivery system for ATFs in vivo. Current studies in our lab are taking advantage 
of non toxic nanoparticles for the delivery of ATF-126 specifically in tumor cells. Specifically, 
the Nan particles will have a ligand for CD44 which is only expressed in cancer cells. 
Briefly, tumors will be established in the mice by implanting MDA-MB-231 expressing 
luciferase subcutaneously. Then, the nano-particles containing ATF-126 will be injected via 
tail vein and the tumors will be monitored by bioluminescence imaging (BLI) over time to 
assess eventual tumor reduction. 
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